SCODiA Report by MLBI Lab

Single-Cell Analysis of the Colon Cancer Microenvironment: Cellular Interactions, Marker Expression, and Therapeutic Targets

This report details a single-cell RNA sequencing analysis of colon cancer, identifying significant shifts in cellular composition, genomic stability, and communication networks within the tumor microenvironment. We observe the expansion of aneuploid intestinal epithelial cells, increased immunosuppressive T cell subsets, and a complex macrophage landscape. The analysis highlights widespread dysregulation in cell-cell interactions, surface marker expression, and key signaling pathways that drive tumor progression and immune evasion, offering insights into potential therapeutic vulnerabilities.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy
2. UMAP Visualization of Major Cell Type Scores and Annotations
3. Marker Expression Dot Plot for Cell Subtypes
4. Copy Number Variation Analysis in Intestinal Epithelial Cells
5. UMAP Visualization of CNV Patterns Across Cell Types, Ploidy, Condition, and Samples
6. Cell Type Composition Differences in Colon Cancer and Adjacent Normal Tissues
7. T Cell Subset Population Analysis in Colon Cancer
8. Analysis of T cell Subset Population Changes in Colon Tumor Microenvironment
9. Macrophage Subset Population Analysis in Colon Cancer
10. Elevated Macrophage Subpopulations in Colon Tumor Microenvironment
11. Ploidy Status of Intestinal Epithelial Cells in Colon Cancer
12. Cell-Cell Interaction Patterns in Colon Cancer: Tumor vs. Adjacent Normal Tissue
13. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
14. Condition-Specific Cell-Cell Interaction Patterns in Colon Cancer
15. Surfaceome Marker Expression in Intestinal Epithelial Cells of Colon Cancer
16. Macrophage Condition-Specific Surfaceome Marker Analysis in Colon Cancer
17. Fibroblast Condition-Specific Surfaceome Markers in Colon Cancer
18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Cancer
19. Differential Expression of Cell Cycle Pathway Genes in Colon Cancer Intestinal Epithelial Cells
20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colon Cancer
21. Gene Set Enrichment Analysis (GSEA) Across Cell Types and Conditions in Colon Tissue
22. Discussion
23. Query List

0. Dataset overview

Dataset Summary

• Dataset Dimensions: Contains data for 63,689 cells and 23,387 genes.
• Species and Tissue: The data is from human colon tissue.
• Conditions: Two main conditions are present: 'Tumor' and 'Adj_normal', with 'Adj_normal' serving as the reference for differential analyses.
• Cell Type Annotations: Cells are categorized into hierarchical levels: celltype_major (e.g., Intestinal Epithelial cell, Stromal cell), celltype_minor (e.g., Fibroblast, Macrophage), and celltype_subset (e.g., Goblet cell, T cell (Cytotoxic)).
• Tumor Origin and Ploidy: The resolved tumor-origin cell type is identified as 'Intestinal Epithelial cell'. The dataset shows 77.4% Diploid cells, 22.4% Aneuploid cells, and 0.2% Unclear ploidy.
• CNV Estimates: Copy Number Variation (CNV) estimates are available within the dataset.
• Precomputed Analysis Results: The dataset includes precomputed results for:
• Cell-Cell Interaction (CCI): Stored per condition (uns['CCI']) and per sample (uns['CCI_sample']).
• Differential Expression Genes (DEG): Results for each celltype_minor comparing one condition vs. the rest (uns['DEG']).
• Gene Set Enrichment Analysis (GSEA): Results for each celltype_minor comparing one condition vs. the rest (uns['GSEA']).
• Gene Ontology (GO/GSA): Results (up-regulated) for each celltype_minor comparing one condition vs. the rest (uns['GSA_up']).
• Inferred Biological Context: Based on the 'Tumor' condition, 'Adj_normal' reference, 'Intestinal Epithelial cell' as tumor-origin, 'Colon' tissue, and aneuploidy rates, the dataset is inferred to be related to Colon Cancer research.

1. UMAP Visualization of Cell Populations by Condition, Sample, Cell Type, and Ploidy

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, providing a comprehensive visualization of the single-cell RNA-sequencing data. These UMAPs display the relationships between individual cells based on their gene expression profiles, colored by various annotations: experimental condition (Tumor/Adj_normal), individual sample, major cell type, minor cell type, inferred ploidy status, and detailed cell type subsets. This visualization allows for the assessment of dataset structure, quality of cell type annotations, and the distribution of different biological characteristics across the cellular landscape.

Visual Summary

Condition

The UMAP colored by condition reveals a clear distinction between cells from Adj_normal (burgundy) and Tumor (dark blue) tissues in many regions of the embedding. Distinct clusters are predominantly populated by either Tumor or Adj_normal cells, indicating condition-specific transcriptional programs. However, significant intermingling is also observed in several central regions, suggesting the presence of shared cell populations or cells undergoing transition between conditions, particularly within the tumor microenvironment.

Sample

The sample UMAP shows that cells from individual samples (represented by various colors) are generally well-integrated and distributed across the major cell clusters. This suggests that potential batch effects originating from different patients or processing batches have been largely mitigated, allowing for meaningful biological comparisons. While overall integration is good, some minor enrichment of specific samples can be observed in certain clusters, which may reflect patient-specific biological heterogeneity.

Celltype Major, Minor, and Subset

The UMAPs colored by celltype_major, celltype_minor, and celltype_subset demonstrate a robust and hierarchical organization of cell populations:

• celltype_major: Major cell types such as Intestinal Epithelial cell (Ent.Epi - orange), T cell (dark blue), Myeloid cell (light yellow), and Stromal cell (light green) form distinct, well-separated clusters, indicating clear transcriptional identities. B cell (dark red) and Plasma cell (light blue) also form noticeable, smaller clusters. The unassigned cells (purple) are sparsely distributed.
• celltype_minor: This provides finer resolution, resolving major types into T cell CD4+, T cell CD8+, Macrophage, Fibroblast, and various Intestinal Epithelial cell components. These minor types maintain largely distinct groupings, supporting the quality of annotation.
• celltype_subset: The most granular annotation shows even further refined populations like Goblet cell, Crypt cell, specific Macrophage (M1, M2A, M2B, M2C, M2D) subtypes, and various T cell (CD4 Memory, Cytotoxic, Treg) populations. These subsets often form sub-clusters within their respective minor cell type groups, reinforcing the detailed characterization of the cellular landscape.

Ploidy_dec

The ploidy_dec UMAP provides a crucial insight into genomic stability. A significant portion of the cells are classified as Diploid (light yellow) and are broadly distributed across the UMAP, particularly in clusters corresponding to immune and stromal cells, and some epithelial cells. In contrast, Aneuploid cells (dark red) are highly concentrated within a large, distinct cluster that largely overlaps with the Intestinal Epithelial cell population identified in the celltype_major plot. A very small number of Unclear cells (dark blue) are scattered.

Biological Interpretation

Tumor-Specific Cell Populations and Aneuploidy

The observed co-localization of the Aneuploid state with a predominant Intestinal Epithelial cell cluster strongly supports the identification of this epithelial population as tumor cells. This finding is consistent with the inferred disease context of Colon Cancer, where intestinal epithelial cells are the tumor-origin cell type, and aneuploidy is a hallmark of cancerous transformation. The distinct separation of many Tumor cells from Adj_normal on the condition UMAP, particularly in the region enriched for aneuploid epithelial cells, highlights significant transcriptional differences driven by oncogenesis.

Heterogeneous Tumor Microenvironment

The UMAPs reveal a complex and heterogeneous tumor microenvironment. While epithelial tumor cells form a core, various immune cells (e.g., T cells, B cells, macrophages, plasma cells) and stromal cells (e.g., fibroblasts, endothelial cells) are present across both tumor and adjacent normal regions, indicating a dynamic interplay between different cell types in disease progression. The detailed celltype_minor and celltype_subset annotations allow for granular investigation into the specific roles of immune and stromal subpopulations, such as different macrophage activation states or T cell effector/regulatory subsets, within the distinct contexts of tumor and normal tissue.

Annotation Quality and Dataset Structure

The clear segregation of distinct cell types and subtypes across the UMAPs, from major classifications down to granular subsets, indicates high-quality cell type annotation and a well-resolved cellular landscape. The hierarchical consistency across celltype_major, celltype_minor, and celltype_subset suggests that the clustering and annotation accurately reflect underlying biological distinctions in gene expression. This robust annotation forms a strong foundation for subsequent differential expression, pathway, and cell-cell interaction analyses.

Annotation Notes

• The 'unassigned' cells across the celltype_major, celltype_minor, and celltype_subset UMAPs represent a small fraction of the total cell count. Their scattered distribution might suggest they are low-quality cells, transitional cell states, or rare cell types not yet clearly defined. Further investigation or re-clustering of these cells could provide additional insights.
• While Aneuploid cells largely define the tumor epithelial compartment, the presence of Diploid cells within the Tumor condition, particularly in regions corresponding to immune or stromal cells, is expected as these cells often infiltrate the tumor without necessarily being aneuploid themselves.
• The Unclear ploidy label is very minor (0.2%) and appears diffusely distributed, suggesting these are not a specific biological population but rather cells for which ploidy status could not be confidently determined, potentially due to technical reasons or intermediate states.

2. UMAP Visualization of Major Cell Type Scores and Annotations

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the global single-cell RNA-seq landscape of human colon tissue. The plots display computed scores for major cell types, along with categorical annotations for cell type (celltype_major) and ploidy status (ploidy_dec). These visualizations are crucial for assessing the quality of cell type annotations, understanding cellular heterogeneity, and identifying the spatial distribution of distinct cell populations within the inferred colon cancer context.

Visual Summary

The UMAP embedding effectively separates cells into distinct clusters, reflecting underlying biological differences.

• Major Cell Type Scores: Each plot for HiCAT_major_score (e.g., T cell, Plasma cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Enteric neuron, Intestinal Epithelial cell) shows regions of high score (yellow/green) that delineate specific, well-defined clusters on the UMAP. This indicates that the calculated scores accurately capture the transcriptional identity of these major cell types, leading to distinct spatial separation on the embedding.
• Intestinal Epithelial Cells and Ploidy: A prominent cluster located in the top-left region of the UMAP exhibits high scores for Intestinal Epithelial cell. Critically, this cluster shows a strong spatial overlap with cells designated as Aneuploid (maroon color in the ploidy_dec plot). The remaining clusters are predominantly Diploid (light yellow).
• Immune and Stromal Cell Distribution: Immune cells (e.g., T cells, B cells, Plasma cells, Myeloid cells, Mast cells) and stromal cells (e.g., Fibroblasts, Endothelial cells, Smooth muscle cells, Enteric neurons) form distinct and largely separate clusters from the Intestinal Epithelial/Aneuploid cluster. For example, T cells cluster distinctly in the upper-right, Myeloid cells in the mid-left, and Stromal cells in the bottom-right.
• celltype_major Annotation: The celltype_major plot displays discrete, color-coded clusters for each major cell type, which are highly consistent with the regions showing high scores in the individual HiCAT_major_score plots. This confirms the coherence between continuous scoring and categorical annotation.

Biological Interpretation

The strong concordance between the major cell type scores and the discrete celltype_major annotations suggests robust cell type identification within this single-cell dataset.

• Tumor-Origin Cell Identification: The observed co-localization of high Intestinal Epithelial cell scores with Aneuploid cells provides compelling evidence for their tumor origin, aligning with the inferred colon cancer context and the resolution of Intestinal Epithelial cell as the tumor-origin cell type. Aneuploidy is a hallmark of cancer, indicating chromosomal instability and abnormal chromosome numbers, which is frequently observed in epithelial-derived malignancies like colon cancer [Reference: PubMed search for "aneuploidy colon cancer"].
• Tumor Microenvironment Composition: The clear separation of various immune cell types (T cells, B cells, Myeloid cells, Plasma cells, Mast cells) and stromal cells (Fibroblasts, Endothelial cells) into distinct UMAP clusters, spatially distinct from the aneuploid epithelial compartment, highlights the complex cellular heterogeneity of the tumor microenvironment (TME). This indicates the presence of diverse immune infiltration and stromal remodeling, which are crucial factors influencing tumor progression, immune surveillance, and therapeutic responses in colon cancer [Reference: PubMed search for "colon cancer tumor microenvironment"].
• Cell Type Purity: The distinct clustering of different cell types and the clear segregation of aneuploid cells from diploid populations underscore the high quality of single-cell resolution and annotation, allowing for downstream cell-type-specific analyses to be performed with confidence.

Annotation Notes

• The UMAP plots clearly demonstrate that the HiCAT_major_score metrics effectively capture the unique transcriptional profiles of different cell types, resulting in well-separated clusters.
• There is a high degree of consistency between the continuous HiCAT_major_score heatmaps and the discrete celltype_major categorical assignments, indicating robust and accurate cell type annotation across the dataset.
• The clear demarcation between Aneuploid and Diploid cells, especially the strong association of aneuploidy with the Intestinal Epithelial cell cluster, validates the ploidy_dec classification and strengthens the identification of the cancerous cell population.
• The visualization indicates that most cells are assigned to a major cell type, with a small unassigned population, suggesting comprehensive coverage of the major cellular constituents in the sample.

3. Marker Expression Dot Plot for Cell Subtypes

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot for the celltype_subset annotations within the single-cell RNA-seq dataset. The plot visualizes the mean expression level (color intensity) and the fraction of cells expressing a gene (dot size) for a selection of marker genes across all identified cell subtypes. This analysis serves as a crucial quality control step to validate the accuracy and specificity of the cell type annotations, confirming that each cell cluster expresses expected lineage-specific genes. The output supports an annotation and identity-check interpretation, ensuring that the assigned cell identities are robustly supported by their gene expression profiles.

Interpretation of Cell Marker Expression

The dot plot reveals distinct and highly specific marker gene expression patterns for nearly all celltype_subset populations, indicating robust and well-defined cell type annotations.

• Clear Cell Type Delineation: A prominent diagonal pattern of large, dark red dots (high expression in a large fraction of cells) is observed across the plot. This indicates that each celltype_subset is characterized by a unique set of marker genes, which are largely confined to their respective cell type and show minimal expression in other populations. This strong specificity is visually emphasized by the red boxes highlighting these highly specific marker blocks for most cell types.

Validation of Major Cell Lineages:

• Immune Cells: B cell subtypes (B cell (Breg), B cell (Follicular), B cell (MZ), B cell (Memory)) are clearly marked by canonical genes such as *CD79A*, *CD79B*, and *MS4A1*. Similarly, T cell subtypes display robust expression of pan-T cell markers like *CD3D*, *CD3E*, and *CD3G*, with further differentiation by *CD4* for CD4+ T cells and *CD8A*, *CD8B* for CD8+ T cells. NK cells are identified by *NKG7*, *GZMA*, *GZMB*, and *KLRD1*. Macrophages (M1, M2A, M2B, M2C, M2D) are broadly marked by *CD68* and *CD14*. Plasma cells exhibit specific expression of *JCHAIN*, *MZB1*, and *XBP1*. Mast cells are characterized by *TPSAB1*. Dendritic cell subtypes (DC (Plasmacytoid), DC (Classical), DC (Inflammatory)) also show distinct marker expression.
• Stromal Cells: Fibroblasts are strongly identified by genes such as *DCN*, *LUM*, *COL1A1*, *COL1A2*, *COL3A1*, and *COL6A2*. Smooth muscle cells show specific expression of *ACTA2*, *MYL9*, and *TAGLN*.
• Endothelial Cells: Endothelial cell populations (Endothelial cell, Endothelial tip cell, Lymphatic Endothelial cell) are clearly distinguished by markers like *PECAM1*, *VWF*, and *FLT1*.
• Enteric Glial Cells: These cells are well-defined by specific markers like *S100B*.
• Granular Intestinal Epithelial Cell Subtypes: The analysis provides a highly resolved view of the Intestinal Epithelial cell compartment, which is critical in colon tissue and cancer. Subtypes such as Crypt cell, Enterocyte, Goblet cell, Microfold cell, Paneth cell, Tuft cell, Enterochromaffin cell, and Enteroendocrine cell are successfully distinguished by their unique marker profiles. For instance, Goblet cells are marked by *MUC2* and *TFF3*, Paneth cells by *LYZ*, Enterocytes by *FABP1* and *CDX2*, and Enteroendocrine cells by *CHGA* and *SCG2*. This level of detail confirms a comprehensive characterization of the epithelial lineage.
• Prevalence and Expression Levels: For most cell types, their specific markers are expressed in a high fraction of cells within that group (large dot size) and at high mean expression levels (dark red color), reinforcing the reliability of the cell type assignments.
• Common Markers: A distinct "common markers" column shows genes that are expressed broadly across multiple cell types. These genes are appropriately recognized as pan-cellular or housekeeping-like and do not contribute to distinguishing specific cell subtypes, which is consistent with their labeling.

Annotation Notes

• High Annotation Quality: The visually striking, specific, and strong expression of known marker genes for each celltype_subset provides strong evidence for the high quality and accuracy of the cell type annotations. The detailed resolution, especially within the Intestinal Epithelial and immune cell compartments, suggests a robust clustering and annotation workflow.
• Biologically Plausible Subtypes: The identified markers for each celltype_subset are consistent with established biological knowledge of cell identity in human colon tissue and its associated immune microenvironment. This includes specialized epithelial cells of the intestine, diverse immune populations, and stromal components.
• Foundation for Downstream Analysis: The confidence in celltype_subset annotations established by this marker plot is critical for interpreting subsequent differential expression, gene set enrichment, and cell-cell interaction analyses. Reliable cell identities ensure that biological insights derived from these analyses are accurately attributed to specific cell populations.

4. Copy Number Variation Analysis in Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) specifically within the Intestinal Epithelial cell population, which has been identified as the resolved tumor-origin cell type in this colon tissue dataset. The primary goal is to identify genomic regions with significant amplifications or deletions, especially when comparing tumor samples to adjacent normal tissue. The results are presented as a log2(Copy Number Ratio) heatmap across genomic spots, grouped by sample, and a summarized heatmap highlighting regions with significantly amplified copy numbers and their frequency across tumor samples. This provides insights into the genomic instability characteristic of cancer development in these specific cells.

Visual Summary

CNV Heatmap (log2(CNR) by Genomic Spot and Sample)

The heatmap displays log2(Copy Number Ratio) values, where red indicates amplification (log2(CNR) > 0) and blue indicates deletion (log2(CNR) < 0).

• Adjacent Normal Samples (SMCxx-N): Samples identified as 'SMCxx-N' (e.g., SMC01-N, SMC02-N) generally exhibit minimal to no significant CNVs, showing a mostly neutral (white) signal, as expected for non-malignant cells. Some minor fluctuations might represent normal genomic variability or localized cell-level noise.
• Diploid Tumor Samples (Diploid SMCxx-T): Intriguingly, some tumor samples initially classified as 'Diploid' (e.g., Diploid SMC08-T, Diploid SMC10-T) show subtle yet distinct CNV patterns. For instance, Diploid SMC08-T shows amplifications on chromosome 7 and 8, while Diploid SMC10-T shows deletions on chromosome 1 and 18. This suggests that even cells categorized as diploid by initial broader ploidy estimation can harbor specific regional CNVs, highlighting the resolution of single-cell CNV analysis.
• Tumor Samples (SMCxx-T): The majority of tumor samples ('SMCxx-T') display widespread and significant CNVs, characterized by prominent red (amplification) and blue (deletion) regions across multiple chromosomes.
• Recurrent Amplifications: Strong and consistent amplifications are frequently observed on chromosomes 7, 8, 19, and 20 across many tumor samples (e.g., SMC01-T, SMC04-T, SMC07-T, SMC08-T, SMC09-T, SMC14-T, SMC15-T, SMC17-T, SMC18-T, SMC19-T, SMC20-T, SMC21-T, SMC22-T, SMC23-T, SMC24-T, SMC25-T).
• Recurrent Deletions: Notably, chromosome 18 shows consistent deletions across a large subset of tumor samples. Other chromosomes like 4, 5, 13, 15, and 16 show more sporadic deletion events.

Summary Heatmap of Significantly Amplified Regions

This heatmap quantifies the log2(CNR) values for specific cytogenetic bands with significant amplification across individual tumor samples, along with their frequency of occurrence.

Highly Frequent Amplifications:

• 19q13.43:21q21.3: This region shows the highest frequency of amplification (0.74, meaning it's significantly amplified in 74% of tumor samples). The average log2(CNR) values in affected samples are also notably high, reaching up to 2.8. While the label spans to 21q21.3, the heatmap prominently shows strong amplification on chromosome 20, which is a known hot spot for amplification in colorectal cancer.
• 1q21.3:1q23.1: Amplified in 63% of tumor samples, with log2(CNR) values up to 1.3.
• 7p14.1:7q11.23 (EGFR): This region, containing the *EGFR* gene, is significantly amplified in 58% of tumor samples. Average log2(CNR) values range up to 1.8, indicating substantial gene dosage increases.

Other Significant Amplifications:

• 1q42.2:2p25.3: Observed in 47% of samples.
• 6q27:7p21.1: Observed in 47% of samples.
• 8q21.3:8q24.3 (EIF3E, INT8S): Amplified in 39% of tumor samples, with log2(CNR) values reaching up to 1.8. This region contains *EIF3E* and *ITGB8* (labeled as INT8S).
• 7q22.1:7q31.1: Observed in 37% of samples, close to the *EGFR* region.

Biological Interpretation

The observed CNV patterns in Intestinal Epithelial cells from tumor samples provide strong evidence of genomic instability, a hallmark of cancer.

Oncogenic Amplifications:

• EGFR Amplification (7p14.1:7q11.23): The frequent and significant amplification of the *EGFR* locus is a critical finding. Epidermal Growth Factor Receptor (*EGFR*) is a well-known oncogene whose overexpression or amplification promotes cell proliferation, survival, and metastasis in many cancers, including colorectal cancer. This amplification suggests a potential driver mechanism for tumor growth in these patients. GeneCards: EGFR
• EIF3E and ITGB8 (INT8S) Amplification (8q21.3:8q24.3): The amplification of *EIF3E* (Eukaryotic Translation Initiation Factor 3 Subunit E) suggests increased protein synthesis, which is often dysregulated in cancer to support rapid cell growth and division. *ITGB8* (Integrin Subunit Beta 8) is involved in cell adhesion and signaling, and its amplification could contribute to altered cell-matrix interactions and increased invasiveness. GeneCards: EIF3E, GeneCards: ITGB8
• Chromosome 20q Amplification: The high frequency of amplification on chromosome 20 (likely contributing to the 19q13.43:21q21.3 region in the summary) is consistent with established findings in colorectal cancer, where 20q amplification is a common event associated with tumor progression and adverse prognosis. This region harbors several known oncogenes. PubMed search: Chromosome 20q amplification colorectal cancer
• Chromosome 1q Amplification: Frequent amplification on 1q21.3:1q23.1 is also a known event in colorectal cancer, often associated with tumor progression.

Tumor Suppressor Deletions:

• Chromosome 18 Deletion: The recurrent deletions on chromosome 18 are highly significant. Loss of heterozygosity (LOH) on 18q is one of the most common genomic alterations in colorectal cancer, often associated with the inactivation of tumor suppressor genes like *DCC* (Deleted in Colorectal Carcinoma) and *SMAD4*, which play critical roles in cell differentiation, apoptosis, and growth inhibition. GeneCards: DCC, PubMed search: 18q loss colorectal cancer
• Diploid Tumor Cells: The presence of CNVs in cells initially classified as "Diploid SMCxx-T" underscores the complexity of tumor heterogeneity and the limitations of bulk or less granular ploidy measurements. These cells, despite being broadly diploid, may still harbor specific chromosomal aberrations that contribute to their malignant phenotype or represent intermediate stages of genomic evolution.

Clinical or Translational Implications

The identified CNVs in Intestinal Epithelial cells have several potential clinical implications:

• Biomarkers: Recurrent amplifications (e.g., *EGFR*, Chr20q) and deletions (e.g., Chr18) can serve as diagnostic or prognostic biomarkers for colon cancer progression.
• Therapeutic Targets: The amplification of *EGFR* is particularly relevant, as *EGFR*-targeted therapies are a cornerstone of treatment for a subset of colorectal cancer patients. Identifying *EGFR* amplification at the single-cell level in the tumor-origin cells could help in patient stratification for such treatments.
• Tumor Heterogeneity: The observation of CNVs in "Diploid" tumor cells highlights the genomic heterogeneity within tumors and suggests that a comprehensive single-cell CNV analysis can reveal subclonal populations with distinct genomic alterations that might influence disease course or therapeutic response.
• Disease Mechanisms: These findings provide direct evidence of specific genomic alterations driving disease in the primary tumor cells, contributing to a better understanding of the molecular pathogenesis of colon cancer.

5. UMAP Visualization of CNV Patterns Across Cell Types, Ploidy, Condition, and Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP (Uniform Manifold Approximation and Projection) plots, each visualizing the same single-cell RNA-seq data embedded based on estimated Copy Number Variation (CNV) patterns. The UMAPs are colored by different metadata features: major cell type, minor cell type, ploidy status (diploid or aneuploid), sample condition (Tumor or Adj_normal), and individual sample identifier. The primary goal is to understand how CNV patterns stratify cells, relate to cell identity, and distinguish between disease conditions and samples, providing insights into the dataset's underlying biological structure and annotation quality in the context of colon cancer.

Visual Summary

The UMAP projections reveal clear structural separation driven by CNV patterns across the different annotations:

celltype_major and celltype_minor

• Both major and minor cell type plots show distinct clustering of different cell populations. Immune cells (e.g., T cell, B cell, Myeloid, Plasma cell) tend to form separate, tightly grouped clusters, particularly prominent on the left and bottom regions of the UMAP.
• The Intestinal Epithelial cell population (colored orange/light orange) forms a very large, prominent cluster, primarily located in the upper central and right regions of the UMAP, demonstrating its dominant presence in the dataset and potentially diverse CNV states within this cell type.
• Stromal cells (light green) also form distinct clusters, often spatially separated from the main epithelial mass.
• A small, distinct cluster labeled unassigned (dark purple) is observed on the far left, suggesting a unique CNV signature for these cells.

ploidy_dec

• There is a strikingly clear separation between Aneuploid (dark red) and Diploid (light yellow) cells.
• The Aneuploid cells form a prominent, dense cluster that largely overlaps with the dominant Intestinal Epithelial cell cluster in the upper central and right regions of the UMAP, as well as some smaller distinct clusters.
• Diploid cells constitute the majority and encompass most of the remaining cell types and regions, including the distinct immune and stromal cell clusters.
• A very small number of cells are labeled Unclear (dark purple), appearing scattered.

condition

• The Tumor condition (dark purple) shows substantial overlap with the Aneuploid population and the Intestinal Epithelial cell cluster. This indicates that the aneuploid cells are overwhelmingly derived from tumor samples.
• Adj_normal samples (dark red) predominantly occupy the regions associated with Diploid cells and the immune/stromal clusters, consistent with their non-malignant nature.
• There is some intermixing where Adj_normal cells appear within the Tumor dominant regions, and vice-versa, which is expected as tumor biopsies contain various stromal and immune cells that are often diploid, and adjacent normal tissues can contain some abnormal cells or be affected by tumor proximity.

sample

• The distribution across samples shows a degree of mixing, indicating that cells from different samples generally contribute to the major biological clusters (e.g., epithelial, immune, aneuploid).
• However, specific samples also show distinct contributions to particular regions or sub-clusters, suggesting inter-patient heterogeneity in cellular composition or specific CNV profiles. For example, some 'T' (Tumor) samples contribute heavily to the aneuploid clusters, while 'N' (Normal) samples are concentrated in diploid regions.

Biological Interpretation

The CNV-driven UMAP provides powerful insights into the biological heterogeneity of the colon tissue in the context of cancer:

1. Malignant Cell Identification: The strong co-localization of Aneuploid cells, Tumor condition, and Intestinal Epithelial cell type is a critical finding. This strongly suggests that the aneuploid Intestinal Epithelial cells represent the primary malignant cell population in the colon cancer samples. Aneuploidy is a hallmark of many cancers, arising from chromosomal instability [PubMed Search].
2. Tumor Microenvironment: The Diploid cells, often found in Tumor samples but distinct from the aneuploid cluster, likely represent the diverse cellular components of the tumor microenvironment (TME), including various immune cells (T cells, B cells, macrophages), stromal cells (fibroblasts, endothelial cells, smooth muscle cells), and potentially normal epithelial cells infiltrating or adjacent to the tumor. These cells typically maintain a diploid state even within a tumor.
3. Distinct Biological States: The clear separation of major cell types (epithelial, stromal, immune) and ploidy states (aneuploid vs. diploid) in the CNV embedding validates the underlying biological distinctions captured by the CNV estimation. This indicates that CNV patterns are effective in distinguishing fundamental cellular identities and disease states in this dataset.
4. Unassigned Cell Population: The small, spatially separated unassigned cluster with a unique CNV signature warrants further investigation. These cells might represent rare cell types, technical artifacts with distinct CNV profiles, or cells with unusual chromosomal aberrations not aligning with defined populations.

Annotation Notes

The UMAPs based on CNV patterns demonstrate excellent separation of cell populations based on their inferred chromosomal states, providing strong validation for the ploidy_dec and condition annotations. The distinct clustering of various celltype_major and celltype_minor populations, especially the immune and stromal cells, further supports the quality of the cell type annotations. The clear demarcation between aneuploid (tumor-associated Intestinal Epithelial cells) and diploid cells (normal cells and tumor microenvironment components) aligns well with the expected biology of colon cancer. The presence of inter-sample variability is also observed, which is common in patient-derived data and may reflect true biological heterogeneity or minor sample-specific effects, but does not obscure the major biological distinctions.

6. Cell Type Composition Differences in Colon Cancer and Adjacent Normal Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot visualizing the proportional distribution of minor cell types across individual samples from both 'Adj_normal' (adjacent normal colon tissue) and 'Tumor' (colon tumor tissue) conditions. This comparison provides a high-resolution view of the cellular microenvironment shifts that occur in the context of colon cancer, highlighting changes in the relative abundance of various immune, stromal, and epithelial cell populations.

Visual Summary

The stacked bar plots display the relative proportions of 15 minor cell types, along with an 'unassigned' category, for each sample.

• Intestinal Epithelial Cell Dominance in Tumors: Intestinal Epithelial cells (light orange/yellow) show a marked increase in relative abundance in the majority of tumor samples compared to adjacent normal samples. In many tumor samples (e.g., SMC16-T, SMC22-T, SMC18-T, SMC09-T, SMC20-T, SMC21-T), they constitute the predominant cell population, often exceeding 60-80% of the total cells. In contrast, their proportion in adjacent normal samples is generally lower and more variable.

Immune Cell Alterations:

• T cells (CD4+ and CD8+) (teal and dark blue, respectively) collectively form a substantial portion of the cellular landscape in adjacent normal samples. However, their proportions appear generally reduced in tumor samples.
• Plasma cells (light green) and B cells (maroon) also tend to be proportionally less abundant in the tumor microenvironment compared to adjacent normal tissue.
• Macrophages (light yellow) show a variable presence in both conditions but do not exhibit a consistent dramatic increase or decrease.
• Other immune cell types like Dendritic cells (red) and NK cells (pale green) are present at low proportions in both conditions, with no clear trend of significant enrichment or depletion.

Stromal Cell Dynamics:

• Fibroblasts (orange) appear to be notably enriched in several tumor samples (e.g., SMC17-T, SMC03-T, SMC15-T, SMC06-T) compared to adjacent normal samples, where they constitute a smaller fraction. This suggests an expansion of fibroblast populations within the tumor microenvironment.
• Endothelial cells (red-orange) and Smooth muscle cells (mint green) show variable representation but do not show consistent enrichment in tumor samples.
• Inter-sample Heterogeneity: There is considerable variability in cell type composition among individual tumor samples, indicating diverse microenvironmental landscapes even within the same disease context.

Biological Interpretation

The observed shifts in cell type populations provide crucial insights into the biology of colon cancer:

• Malignant Epithelial Cell Expansion: The significant increase in Intestinal Epithelial cells in tumor samples is consistent with the proliferation and expansion of malignant epithelial cells, which are the primary cellular component of colon adenocarcinoma. This finding aligns with the inference that Intestinal Epithelial cell is the tumor-origin cell type in this dataset.
• Immune Microenvironment Remodeling and Suppression: The reduction in the proportional abundance of key immune cells, including T cells (CD4+ and CD8+), B cells, and Plasma cells, in tumor samples suggests a re-orchestration of the immune microenvironment towards an immune-suppressive or immune-excluded phenotype. This is a common hallmark of cancer progression, where tumor cells evade detection and elimination by the host immune system. A decrease in cytotoxic CD8+ T cells is particularly relevant given their critical role in anti-tumor immunity.
• Stromal Activation (Cancer-Associated Fibroblasts): The observed increase in Fibroblasts within tumor samples points towards the activation and expansion of Cancer-Associated Fibroblasts (CAFs). CAFs are critical components of the tumor microenvironment, playing diverse roles in supporting tumor growth, promoting angiogenesis, remodeling the extracellular matrix, and suppressing anti-tumor immune responses in colon cancer [PMID: 35056976].
• Heterogeneity of Tumor Microenvironment: The sample-to-sample variability in cell type proportions within the tumor group underscores the inherent heterogeneity of colon cancer. This suggests that different tumors might engage distinct mechanisms of immune evasion and stromal support, potentially influencing patient outcomes and therapeutic responses.

Clinical or Translational Implications

The changes in cellular composition identified in this analysis have several important clinical and translational implications for colon cancer:

• Biomarker Discovery: The distinct patterns of immune and stromal cell infiltration in the tumor microenvironment could serve as potential diagnostic, prognostic, or predictive biomarkers. For instance, the ratio of specific immune cell subsets or the abundance of CAFs might correlate with disease stage, progression-free survival, or response to specific therapies.
• Therapeutic Targeting of the Tumor Microenvironment: The observed shifts, particularly the apparent immune suppression and CAF activation, highlight potential therapeutic targets. Strategies aimed at restoring anti-tumor immunity (e.g., immune checkpoint inhibitors, adoptive cell therapies) or depleting/reprogramming CAFs could enhance the efficacy of existing treatments in colon cancer patients [PubMed search: "colon cancer immune microenvironment therapy", "colon cancer CAF therapy"].
• Personalized Medicine: The significant inter-sample heterogeneity observed emphasizes the need for personalized approaches in cancer therapy. Characterizing the specific immune and stromal landscape of an individual patient's tumor could help guide treatment selection, moving towards more effective and patient-specific therapeutic strategies.

7. T Cell Subset Population Analysis in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell and NK cell subsets across individual samples from both 'Adj_normal' (adjacent normal colon tissue) and 'Tumor' (colon tumor tissue) conditions. The data is derived from single-cell RNA-seq, providing a granular view of the immune cell landscape within the colon microenvironment. The aim is to identify shifts in the immune cell composition that may be associated with colon cancer progression or immune response.

Visual Summary

The stacked bar plots display the percentage composition of T cell subsets and NK cells for each sample. Samples are grouped by condition: 'Adj_normal' (left panel) and 'Tumor' (right panel).

1. Dominant Subsets in Adjacent Normal Tissue: In 'Adj_normal' samples, NK cells (dark red), T cell (CD4 Memory) (red), and T cell (CD8 Exhausted) (orange-red) consistently represent a substantial portion of the T cell and NK cell compartment. T cell (Cytotoxic) (light yellow) also contributes significantly. T cell (Treg) (dark blue) is present but generally at lower proportions across most normal samples.
2. Prominent Shifts in Tumor Tissue:

• Increased T cell (Treg) Proportions: A striking and consistent observation in the 'Tumor' samples is the marked increase in the proportion of T cell (Treg) (dark blue) compared to 'Adj_normal' samples. This increase is evident across nearly all tumor samples.
• Reduced NK Cell Proportions: The proportion of NK cells (dark red) appears generally reduced in 'Tumor' samples compared to 'Adj_normal' samples, though their presence varies between individual tumor samples.
• Altered CD8+ T cell States: While T cell (Cytotoxic) (light yellow) and T cell (CD8 Exhausted) (orange-red) remain significant components in tumor samples, there appears to be a tendency for T cell (CD8 Exhausted) to be maintained or even slightly increased in proportion, whereas T cell (CD4 Memory) (red) proportions might be slightly reduced in some tumor samples.
• T Helper Cell Subsets: T cell (Th1) (pale yellow) proportions appear to be somewhat reduced in tumor samples. Other T helper subsets (Th2, Th17, Tfh, Th22, Th9) generally remain minor components in both conditions, with some variability.

3. Inter-sample Heterogeneity: While general trends are observed, there is noticeable heterogeneity in the exact proportions of each T cell subset across different samples within both the 'Adj_normal' and 'Tumor' groups, highlighting patient-specific immune landscapes.

Biological Interpretation

The observed shifts in T cell subset populations in the colon tumor microenvironment provide critical insights into the immune response in colon cancer.

• Immunosuppression by T regulatory cells (Tregs): The most prominent finding is the consistent increase in T cell (Treg) proportions within the tumor. Tregs are crucial in maintaining immune tolerance and suppressing effector T cell responses. Their accumulation in the tumor microenvironment is a well-established mechanism of immune evasion in various cancers, including colorectal cancer, where they inhibit anti-tumor immunity by suppressing cytotoxic T cells and other immune cells [PubMed Search: colorectal cancer Treg infiltration immunosuppression]. This suggests an active immunosuppressive state within the colon tumors in this dataset.
• Impaired Innate Anti-tumor Immunity by NK cells: The general reduction in NK cell proportions in tumor samples is concerning. NK cells are vital components of the innate immune system, capable of directly killing tumor cells, especially those that have downregulated MHC class I molecules. A decrease in NK cells could indicate a weakened innate immune surveillance against the tumor [GeneCards: NCAM1 (CD56, NK cell marker)].
• CD8+ T cell Exhaustion: The sustained or potentially increased proportion of T cell (CD8 Exhausted) in tumor tissue, despite the presence of T cell (Cytotoxic) cells, suggests a potential state of T cell dysfunction. CD8+ T cell exhaustion is characterized by reduced effector function (e.g., cytokine production, cytolytic activity) and sustained expression of inhibitory receptors (e.g., PD-1, CTLA-4) in the context of chronic antigen exposure, often seen in the tumor microenvironment. This functional impairment can hinder effective tumor clearance [PubMed Search: T cell exhaustion tumor microenvironment].
• Shift in T Helper Responses: The apparent reduction in T cell (Th1) in tumor samples could also contribute to immunosuppression. Th1 cells produce pro-inflammatory cytokines like IFN-γ, which are critical for orchestrating effective anti-tumor immune responses [UniProt: P01579 (IFN-gamma)]. A decrease in Th1 relative to other Th subsets or Tregs could tip the balance towards a less effective anti-tumor response.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for colon cancer:

• Biomarker for Prognosis and Response to Immunotherapy: The elevated proportion of Tregs could serve as a prognostic biomarker, potentially indicating a poorer prognosis due to enhanced immune suppression within the tumor. Moreover, the balance between effector T cells (e.g., cytotoxic T cells) and Tregs, or the degree of CD8+ T cell exhaustion, could predict patient response to immunotherapies, particularly immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies) [PubMed Search: T cell exhaustion immunotherapy].

Therapeutic Targets

• Targeting Tregs: Strategies aimed at depleting or inhibiting Tregs, or reversing their suppressive function, could enhance anti-tumor immunity and improve immunotherapy efficacy in colon cancer.
• Enhancing NK Cell Activity: Therapies designed to bolster NK cell numbers or their cytotoxic function within the tumor microenvironment represent another avenue for therapeutic intervention.
• Reversing T cell Exhaustion: Understanding and reversing T cell exhaustion, perhaps through novel checkpoint inhibitors or adoptive cell therapies, is crucial for restoring effective anti-tumor responses.
• Patient Stratification: The observed heterogeneity among tumor samples underscores the need for personalized approaches. Profiling T cell subsets in individual patients could help stratify them for specific immune-modulating therapies.

8. Analysis of T cell Subset Population Changes in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of specific T cell subsets between colon tumor tissue ('Tumor') and adjacent normal tissue ('Adj_normal') derived from single-cell RNA-seq data. The objective was to identify T cell subsets at the 'celltype_subset' taxonomic level within the 'T cell' major population that exhibit statistically significant differences in proportion between the two conditions (p-value < 0.1). The results are visualized using box plots, with each data point representing a sample, illustrating the distribution of cell type proportions across conditions.

Visual Summary

The box plots reveal statistically significant differences in the proportions of five T cell subsets when comparing colon 'Tumor' tissue to 'Adj_normal' tissue:

• Treg cells show a strikingly higher median proportion in the 'Tumor' microenvironment compared to 'Adj_normal' tissue (p = 1.32e-10). The box plot for Treg in 'Tumor' is substantially elevated, indicating a robust enrichment.
• T cell (CD8 Memory) cells exhibit a significantly lower median proportion in 'Tumor' tissue compared to 'Adj_normal' tissue (p = 8.85e-06). This suggests a depletion of this T cell subset within the tumor.
• Th17 cells are observed in significantly higher median proportions in 'Tumor' samples compared to 'Adj_normal' (p = 0.000532).
• Th9 cells also demonstrate a significantly elevated median proportion in the 'Tumor' microenvironment relative to 'Adj_normal' tissue (p = 0.00574), although their overall proportions are relatively low.
• Th22 cells present a significantly increased median proportion in 'Tumor' tissue compared to 'Adj_normal' (p = 0.0168).

Biological Interpretation

The observed alterations in T cell subset populations within the colon tumor microenvironment provide critical insights into the immune landscape of colon cancer, which is known to be characterized by complex immune evasion mechanisms.

• Increased Regulatory T cells (Tregs) in Tumors: The highly significant increase in Treg proportions (p = 1.32e-10) in colon tumors is a well-documented phenomenon in many cancers, including colorectal cancer. Tregs are potent immunosuppressive cells that maintain immune tolerance by suppressing the activity of effector T cells (like CD8+ cytotoxic T cells) and other immune cells. Their enrichment in the tumor microenvironment creates an immunosuppressive milieu that aids tumor immune escape, promoting tumor growth and progression by preventing effective anti-tumor immune responses. (For more on FOXP3, a key marker for Tregs: GeneCards: FOXP3)
• Decreased CD8 Memory T cells in Tumors: The significant reduction of CD8 Memory T cell proportions in tumor tissue (p = 8.85e-06) is particularly concerning. CD8+ cytotoxic T lymphocytes (CTLs) are crucial for directly recognizing and killing cancer cells. A decline in the memory population suggests an impaired ability of the adaptive immune system to mount a sustained and effective anti-tumor response, potentially indicating immune exhaustion or exclusion within the tumor environment.

Elevated Th17, Th9, and Th22 Cells in Tumors:

• Th17 cells (p = 0.000532) are often associated with chronic inflammation. In the context of colorectal cancer, a pro-inflammatory microenvironment driven by Th17 cells and their key cytokine IL-17 is frequently linked to tumor progression, angiogenesis, and metastasis, although their role can be context-dependent. (More on Th17 in cancer: PubMed search: Th17 colorectal cancer progression)
• Th9 cells (p = 0.00574) are also elevated. While Th9 cells can exert anti-tumor effects in some cancers by promoting anti-tumor immunity, their precise role in colorectal cancer is less clear and may depend on the balance of other immune cell types and cytokines, potentially contributing to a complex inflammatory response that might not be effectively anti-tumorigenic in this specific context.
• Th22 cells (p = 0.0168) show an increased proportion. Th22 cells produce IL-22, a cytokine known to promote epithelial cell proliferation, survival, and tissue remodeling. In epithelial-derived cancers like colon cancer, elevated IL-22 signaling has been implicated in enhancing tumor cell growth, survival, and metastasis, thus contributing to disease pathogenesis. (More on IL-22 in cancer: PubMed search: IL-22 colorectal cancer tumor progression)

Taken together, these findings portray an immune microenvironment in colon tumors that is characterized by substantial immunosuppression (high Tregs, low CD8 Memory T cells) and a complex inflammatory milieu (Th17, Th9, Th22), which appears skewed towards supporting tumor growth and immune evasion rather than promoting effective anti-tumor immunity.

Clinical or Translational Implications

The observed shifts in T cell populations hold significant clinical and translational implications for colon cancer:

• Prognostic Biomarkers: The high proportion of Tregs and the reduced proportion of CD8 Memory T cells in the tumor microenvironment could serve as valuable prognostic biomarkers, potentially indicating a poorer prognosis, higher risk of recurrence, or lower response to conventional therapies due to compromised anti-tumor immunity.

Therapeutic Targets:

• Tregs: Strategies aimed at depleting Tregs or inhibiting their immunosuppressive functions could be crucial for unleashing anti-tumor immunity. This might involve novel immunotherapies or adjunct therapies that enhance the efficacy of existing treatments like checkpoint inhibitors. (More on Treg-targeted therapies: PubMed search: Treg depletion cancer therapy)
• CD8 Memory T cells: Developing approaches to boost the numbers and functional capacity of CD8 Memory T cells, possibly through therapeutic vaccination, adoptive cell therapy, or novel immunomodulators, could strengthen the anti-tumor immune response.
• Th17 and Th22: Given their potential pro-tumorigenic roles in colon cancer, modulating the activity of Th17 and Th22 cells or blocking their associated cytokines (e.g., IL-17, IL-22) could represent promising therapeutic avenues to dampen tumor-promoting inflammation and epithelial cell growth.
• Immune Monitoring: Monitoring the relative proportions of these specific T cell subsets in tumor biopsies or even peripheral blood could provide a non-invasive or minimally invasive way to assess disease progression, predict treatment response, and stratify patients for personalized immunotherapeutic strategies.

These insights contribute to a deeper understanding of the immunopathogenesis of colon cancer and highlight specific T cell subsets as potential targets for diagnostic, prognostic, and therapeutic interventions.

9. Macrophage Subset Population Analysis in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative distribution of different macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual patient samples. The samples are categorized into 'Adj_normal' (adjacent normal tissue) and 'Tumor' conditions, providing a comparative view of macrophage polarization states in the context of colon cancer. The visualization helps to identify condition-associated shifts in the macrophage compartment.

Visual Summary

The stacked bar plots display the proportional representation of five macrophage subsets within the total macrophage population for each sample.

• Adj_normal Samples: In adjacent normal colon tissue, the macrophage population generally exhibits a mixed profile. Macrophage (M2B) (light yellow) and Macrophage (M2A) (orange) often constitute a significant portion, suggesting a presence of anti-inflammatory and tissue-repairing phenotypes. Macrophage (M1) (maroon) is also present, with its proportion varying across samples. Macrophage (M2C) (pale yellow) and Macrophage (M2D) (teal) are generally minor components, with one notable exception (SMC03-N) showing a high proportion of Macrophage (M2D).
• Tumor Samples: A distinct shift in macrophage subset distribution is observed in tumor samples. Across the majority of tumor samples, there is a noticeable increase in the relative proportion of Macrophage (M1) (maroon). This subset frequently becomes the most dominant or a significantly increased component within the macrophage population. Concurrently, while Macrophage (M2A) and Macrophage (M2B) are still present, their relative contributions within the macrophage compartment often appear diminished compared to adjacent normal tissues. Macrophage (M2C) and Macrophage (M2D) largely remain minor populations in tumor samples as well.

Biological Interpretation

The observed shift in macrophage subset populations from adjacent normal to tumor tissue highlights significant changes in the tumor microenvironment (TME) of colon cancer. Macrophages are highly plastic immune cells that can differentiate into various functional phenotypes, broadly categorized as M1-like (classically activated) or M2-like (alternatively activated).

• M1 Macrophages: Macrophage (M1) cells are typically characterized by pro-inflammatory cytokine production (e.g., TNF-α, IL-1β) and potent anti-tumorigenic activity, promoting direct tumor cell killing and T cell activation. The increased relative abundance of M1 macrophages in colon tumor samples suggests an attempt by the immune system to mount an anti-tumor response or an inflammatory component within the TME.
• M2 Macrophages: Macrophage (M2) subsets (M2A, M2B, M2C, M2D) are generally associated with anti-inflammatory responses, tissue repair, angiogenesis, and immune suppression. In many cancers, tumor-associated macrophages (TAMs) are skewed towards an M2-like phenotype, which promotes tumor growth, invasion, and metastasis. The relative reduction of Macrophage (M2A) and Macrophage (M2B) in tumor samples (as M1 increases) suggests a relative re-polarization or altered recruitment of macrophages in the tumor context, potentially indicating a more inflammatory state within the macrophage population rather than a purely immunosuppressive one.
• Colon Cancer Context: The inferred disease context of Colon Cancer makes this finding particularly relevant. While TAMs are often considered pro-tumorigenic and M2-skewed, the increased M1 component suggests a more complex immune landscape. This could reflect heterogeneity in patient immune responses, different stages of tumor progression, or varying degrees of immune infiltration and activation. The specific functional implications of this M1 dominance within the colon cancer TME would warrant further investigation, as even M1-like macrophages can sometimes become dysfunctional or be modulated by tumor-derived factors.

Clinical or Translational Implications

The differential distribution of macrophage subsets between normal and tumor tissues in colon cancer carries several potential clinical implications:

• Prognostic Biomarker: The relative proportions of M1 versus M2 macrophages, particularly the observed shift towards M1, could serve as a prognostic indicator for colon cancer patients. A higher M1 signature might correlate with a better prognosis due to a more active anti-tumor immune response, or it could indicate a specific inflammatory subtype of tumor.
• Therapeutic Targeting: Understanding the polarization state of macrophages in the TME could inform immunotherapeutic strategies. If M1 macrophages are indeed protective, strategies to enhance their function or re-polarize existing M2-like TAMs towards an M1 phenotype could be beneficial. Conversely, if M1 macrophages are present but functionally impaired, therapies aimed at restoring their anti-tumorigenic capabilities could be explored. Modulating macrophage populations and their functions represents a promising avenue for colon cancer immunotherapy PubMed: Macrophages in Cancer Immunotherapy.
• Patient Stratification: The variability in macrophage subset profiles across individual tumor samples suggests that patients could be stratified based on their dominant macrophage phenotypes. This stratification might allow for more personalized treatment approaches, selecting therapies most likely to be effective given the specific immune composition of an individual's tumor.

10. Elevated Macrophage Subpopulations in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis utilized box plots to compare the proportions of specific macrophage subsets—Macrophage (M1), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)—between 'Tumor' and 'Adj_normal' conditions in colon tissue. The primary goal was to identify macrophage subsets exhibiting statistically significant differences in their relative cell numbers in the tumor microenvironment.

Visual Summary

The box plots clearly demonstrate a consistent pattern: all four analyzed macrophage subsets—Mac (M1), Mac (M2B), Mac (M2C), and Mac (M2D)—show significantly higher celltype proportions in the 'Tumor' condition compared to the 'Adj_normal' condition.

• Mac (M1): The proportion of M1 macrophages is substantially elevated in tumors (median ~4-5%) compared to adjacent normal tissue (median <1%), with high statistical significance (p=2.87e-05).
• Mac (M2B): Similarly, M2B macrophages exhibit a significantly increased proportion in tumors (median ~3-4%) versus adjacent normal tissue (median <1%), supported by a p-value of 0.000249.
• Mac (M2C): This subset also shows a marked increase in tumor samples (median ~1.5-2%) compared to adjacent normal tissue (median <0.5%), with a p-value of 0.000357.
• Mac (M2D): M2D macrophages are found in significantly higher proportions in tumors (median ~0.2-0.3%) compared to adjacent normal tissue (median near 0%), indicated by a p-value of 0.00106.

Across all depicted macrophage subsets, the interquartile range (IQR) and overall distribution of proportions are notably wider and higher in the 'Tumor' samples, reflecting both greater variability and generally increased absolute numbers of these cells within the tumor microenvironment.

Biological Interpretation

Macrophages are key immune cells within the tumor microenvironment (TME) and are often broadly categorized into M1 (classically activated) and M2 (alternatively activated) phenotypes, each playing distinct and often opposing roles in cancer progression. The observed significant enrichment of all four macrophage subsets—M1, M2B, M2C, and M2D—in colon tumor tissue compared to adjacent normal tissue signifies a pronounced immune cell infiltration and a substantial re-programming of the myeloid compartment in colon cancer.

• Increased Mac (M1) cells: The elevated presence of M1 macrophages in tumors, typically associated with pro-inflammatory responses and anti-tumor immunity, suggests an active, though potentially insufficient or modulated, attempt by the host immune system to suppress tumor growth.
• Increased M2-like Macrophages (M2B, M2C, M2D): The significant increase in the M2B, M2C, and M2D macrophage subsets is particularly relevant in the context of cancer. M2-like macrophages, often collectively referred to as Tumor-Associated Macrophages (TAMs), are generally implicated in pro-tumorigenic functions. These functions include promoting angiogenesis, suppressing anti-tumor immunity, facilitating tissue remodeling, and contributing to tumor growth and metastasis.
• M2B macrophages are known to participate in immune regulation and can contribute to both pro-inflammatory and anti-inflammatory responses.
• M2C macrophages are typically immunosuppressive, involved in tissue repair, and can support tumor growth by dampening effective anti-tumor immune responses.
• M2D macrophages (a subset frequently identified as having strong pro-tumorigenic roles) are often linked to processes such as angiogenesis and metastasis.

The co-existence and expansion of both M1 and various M2-like macrophage populations highlight the complex and plastic nature of macrophages within the colon cancer TME. While M1 macrophages might represent a beneficial anti-tumorigenic signal, the strong concomitant presence of M2-like subsets often indicates a highly immunosuppressive and pro-tumorigenic environment where anti-tumor immune efforts may be neutralized or circumvented, ultimately contributing to disease progression.

Clinical or Translational Implications

The distinct and significant increase in diverse macrophage subsets within colon tumors has several important clinical and translational implications:

• Immunosuppressive Microenvironment: The high prevalence of M2-like macrophages (M2B, M2C, M2D) strongly suggests the establishment of an immunosuppressive tumor microenvironment in colon cancer. This could contribute to resistance to certain immunotherapies that rely on robust T-cell mediated anti-tumor responses.
• Prognostic Biomarkers: The proportions and specific phenotypes of macrophage subsets, particularly the M2-like populations, could serve as valuable prognostic biomarkers for colon cancer patients, potentially correlating with disease progression, recurrence, or response to therapy.
• Therapeutic Targets: Macrophages, especially the pro-tumorigenic M2-like subsets, represent attractive therapeutic targets. Strategies aimed at depleting TAMs, repolarizing M2 macrophages towards a more anti-tumor M1 phenotype, or inhibiting their specific pro-tumor functions (e.g., angiogenesis, immune suppression) could enhance the efficacy of existing treatments or offer novel therapeutic avenues for colon cancer. For instance, inhibitors targeting CSF1R, which is crucial for macrophage survival and differentiation, are being explored to modulate TAM populations [1]. Furthermore, understanding the specific pathways driving M2 polarization could lead to targeted interventions [2].

---

References:

[1] CSF1R inhibitors in cancer: targeting macrophages to improve immunotherapy. *Journal of Hematology & Oncology*. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=CSF1R+inhibitors+cancer+macrophage

[2] Macrophage polarization and its impact on disease. *Nature Reviews Immunology*. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+polarization+cancer+therapy

11. Ploidy Status of Intestinal Epithelial Cells in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of Intestinal Epithelial cells across different samples from 'Adj_normal' (adjacent normal tissue) and 'Tumor' conditions. The plot_celltype_population tool was used to visualize the proportions of these ploidy populations, providing insights into genomic stability within the presumed tumor-origin cell type. The inferred biological context is Colon Cancer, with Intestinal Epithelial cells identified as the resolved tumor-origin cell type.

Visual Summary

The visualization consists of two bar plots, one for 'Adj_normal' samples and one for 'Tumor' samples, displaying the percentage of cells classified as Aneuploid (maroon), Diploid (light orange), or Unclear (light green) within the Intestinal Epithelial cell population for each sample.

• Adjacent Normal Samples (Adj_normal): All Intestinal Epithelial cells in the 'Adj_normal' samples (SMC03-N to SMC10-N) are almost exclusively diploid. There is virtually no presence of aneuploid or unclear cells, indicating high genomic stability in normal colon tissue.
• Tumor Samples (Tumor): In contrast, the 'Tumor' samples (SMC21-T to SMC19-T) show a striking shift towards aneuploidy within the Intestinal Epithelial cell population.
• Many tumor samples, such as SMC21-T, SMC16-T, and SMC09-T, exhibit a very high proportion of aneuploid cells, often exceeding 90%.
• The proportion of aneuploid cells varies considerably across different tumor samples, ranging from nearly 100% in some to approximately 30% in others (e.g., SMC19-T), indicating significant inter-sample heterogeneity.
• The diploid cell population is inversely correlated with aneuploidy, being minimal in highly aneuploid tumors and more substantial in tumors with lower aneuploid proportions.
• The 'Unclear' ploidy population remains a minor fraction across both conditions but is slightly more discernible in some tumor samples compared to the adjacent normal tissue.

Biological Interpretation

The observed ploidy patterns strongly support the inferred context of Colon Cancer and highlight a fundamental difference in genomic integrity between normal and cancerous Intestinal Epithelial cells.

• Genomic Stability in Normal Tissue: The near-complete diploidy of Intestinal Epithelial cells in adjacent normal samples is consistent with the healthy physiological state, where cells maintain a stable chromosomal complement. This serves as an excellent internal control.
• Aneuploidy as a Hallmark of Cancer: The dramatic increase in aneuploid Intestinal Epithelial cells within tumor samples is a classic hallmark of cancer. Aneuploidy, or an abnormal number of chromosomes, is a pervasive feature of most human cancers, including colorectal cancer. It arises from genomic instability and contributes to tumor heterogeneity, evolution, and malignant progression PubMed: 28980521. The identification of these aneuploid cells specifically within the 'Intestinal Epithelial cell' population reinforces their role as the tumor-origin cells in this colon cancer dataset.
• Inter-Tumor Heterogeneity: The variability in the percentage of aneuploid cells among different tumor samples suggests diverse levels of genomic instability or different stages of tumor evolution across patients. Some tumors may be more genomically unstable and thus more aneuploid, while others might represent earlier stages or different molecular subtypes with less pronounced aneuploidy. This heterogeneity is a known characteristic of colorectal cancer PubMed: 32057999.

Clinical or Translational Implications

• Diagnostic and Prognostic Relevance: The presence and degree of aneuploidy in Intestinal Epithelial cells can serve as a diagnostic marker for colon cancer. Furthermore, the extent of aneuploidy is often associated with tumor aggressiveness, prognosis, and response to therapy in various cancers. Highly aneuploid tumors can have different clinical behaviors and therapeutic sensitivities compared to near-diploid tumors GeneCards: Aneuploidy.
• Therapeutic Considerations: Understanding the ploidy landscape of tumor cells could potentially inform treatment strategies. For instance, some therapies might be more effective against highly aneuploid cells that are under specific replication stress, while others might be tailored for more genomically stable tumor cells. The observed heterogeneity suggests that a "one-size-fits-all" approach to treatment may not be optimal for colon cancer.

12. Cell-Cell Interaction Patterns in Colon Cancer: Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using single-cell RNA sequencing data from colon tissue, comparing the 'Tumor' condition with 'Adj_normal' (adjacent normal) tissue. The primary goal is to identify how cell communication networks involving Intestinal Epithelial cells, Fibroblast cells, Macrophage cells, T cells, and other relevant cell types are altered in the context of colon cancer. The results are presented as dot plots, where the size of the dot represents the significance of the interaction (p-value) and the color intensity reflects the average expression level (mean) of the ligand-receptor pair. Importantly, the analysis distinguishes between 'Diploid Intestinal Epithelial cells' (predominantly in normal tissue) and 'Aneuploid Intestinal Epithelial cells' (likely representing tumor cells), given that Intestinal Epithelial cells are the inferred tumor-origin cell type.

Visual Summary

CCI for Adj_normal

The plot for the 'Adj_normal' condition reveals a diverse and extensive network of cell-cell interactions.

• Broad Connectivity: Many cell types, including Fibroblasts, Endothelial cells, Plasma cells, Intestinal Epithelial cells (specifically 'Diploid Intestinal Epi'), and various T cell subsets, show active communication.
• Key Interaction Partners: Fibroblasts exhibit a wide range of interactions with Plasma cells, Endothelial cells, T cells, and Intestinal Epithelial cells. Similarly, Endothelial cells interact significantly with Fibroblasts and various immune cells.
• Prominent Ligand-Receptor Pairs: Common interaction pairs involve adhesion molecules such as various integrin complexes (e.g., COL1A1-integrin, FBN1-integrin), CD99, ICAM1-integrin, and chemokine signaling like CXCL12-CXCR4. Additionally, molecules like HLA-E and various SEMA (Semaphorin) family members are involved in immune and developmental processes.

CCI for Tumor

The 'Tumor' condition plot shows a marked shift in the cell-cell interaction landscape, characterized by distinct patterns involving tumor-associated cell types.

• Emergence of Aneuploid Epithelial Cell as a Hub: 'Aneuploid Intestinal Epi' cells become a central player, exhibiting strong homotypic interactions and extensive communication with immune cells, particularly Macrophages and T cells (CD4+, CD8+).
• Dominance of Macrophage Interactions: Macrophages display a highly active interaction profile, engaging with Aneuploid Intestinal Epithelial cells, T cells, and other Macrophages.
• Altered Immune Cell Interactions: T cells (CD4+ and CD8+) show increased interactions with Aneuploid Intestinal Epithelial cells and Macrophages, indicating active immune infiltration and crosstalk within the tumor microenvironment (TME).

Key Ligand-Receptor Pairs in Tumor:

• SPP1-integrin family: This axis is highly prominent, particularly involving Macrophage-Macrophage and Macrophage-Aneuploid Intestinal Epi cell interactions, suggesting its critical role in the TME.
• CEACAM5-CEACAM5: Strong homotypic interactions among Aneuploid Intestinal Epi cells are observed, indicating altered cell adhesion and potential cancer-specific signaling.
• PLAUR-uPAR_complex: Interactions involving this complex are present in both Aneuploid Intestinal Epi and Macrophage cells, often associated with cell migration and invasion.
• TNFSF/TNFRSF family: Interactions such as TNFSF13B-TNFRSF13B are seen, particularly involving Macrophages and T cells, which are critical for immune cell survival and function.
• ICAM1-integrin, CD99: These adhesion molecules remain significant, mediating interactions among immune cells and between immune cells and tumor cells.

Biological Interpretation

The observed shifts in cell-cell interaction patterns between adjacent normal tissue and tumor tissue provide critical insights into the colon cancer microenvironment.

1. Tumor Cell-Immune Cell Crosstalk: The most striking change in the tumor microenvironment is the strong and specific interaction between 'Aneuploid Intestinal Epi' cells (presumed tumor cells) and immune cells, particularly Macrophages and T cells. This highlights the intense communication that dictates tumor progression, immune evasion, and potential response to therapy.
2. Role of Macrophages in the TME: The extensive involvement of Macrophages, especially through the SPP1-integrin axis, suggests a significant pro-tumorigenic role. SPP1 (Osteopontin) is a known matricellular protein that promotes tumor growth, metastasis, angiogenesis, and immunosuppression by modulating macrophage polarization and function within the TME. GeneCards: SPP1
3. Tumor Cell Adhesion and Signaling: The strong homotypic CEACAM5-CEACAM5 interactions among Aneuploid Intestinal Epithelial cells are highly relevant. CEACAM5 is a well-established cell surface glycoprotein overexpressed in colon cancer, contributing to cell adhesion, anti-apoptotic signaling, and metastasis. GeneCards: CEACAM5
4. Invasion and ECM Remodeling: The presence of PLAUR-uPAR complex interactions involving tumor cells and macrophages points towards enhanced proteolytic activity, cell migration, and invasion, crucial processes in cancer progression and metastasis. The altered integrin interactions (e.g., LAMC1-integrin) also suggest active remodeling of the extracellular matrix (ECM) supporting tumor growth. GeneCards: PLAUR
5. Immune Modulation: Interactions involving HLA-E and TNFSF/TNFRSF families (e.g., TNFSF13B-TNFRSF13B) suggest active immune regulatory mechanisms within the tumor. HLA-E interactions can modulate NK cell and T cell responses, potentially leading to immune evasion. TNFSF13B (BAFF) plays a critical role in B cell survival and maturation, and its presence might indicate a specific role for B cells or plasma cells in the tumor context, even if not explicitly highlighted in the top 80 pairs for specific B cell-tumor cell interactions.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer promising avenues for therapeutic intervention and biomarker discovery in colon cancer.

1. Targeting the SPP1-Integrin Axis: Given its central role in Macrophage-tumor cell communication and association with tumor progression, targeting SPP1 or its specific integrin receptors (e.g., ITGB1, ITGA5) could be a viable therapeutic strategy to inhibit tumor growth, metastasis, and reprogram the immunosuppressive TME. This could involve small molecule inhibitors or neutralizing antibodies.
2. Exploiting CEACAM5: The prominent homotypic CEACAM5 interactions reinforce its potential as a diagnostic and therapeutic target. CEACAM5-targeted antibody-drug conjugates (ADCs) or bispecific antibodies are already under investigation for colon cancer. Monitoring CEACAM5 levels or its interaction patterns could also serve as a prognostic biomarker for disease progression or recurrence.
3. Inhibiting Invasion and Metastasis: Targeting the PLAUR-uPAR complex could represent an anti-metastatic strategy by reducing tumor cell migration and invasion.
4. Immunotherapy Strategies: The altered immune cell interactions, including those involving HLA-E and TNFSF/TNFRSF members, provide potential targets for immunomodulatory therapies. Further investigation into these specific interactions could inform strategies to enhance anti-tumor immunity, for instance, by blocking immunosuppressive pathways or activating effector immune cells.
5. Biomarker Development: The identified ligand-receptor pairs, particularly those exclusive or significantly enhanced in the tumor condition, could serve as novel biomarkers for early detection, prognosis, or prediction of treatment response. For instance, elevated expression of SPP1 or CEACAM5 in circulating tumor cells or plasma could indicate disease presence or progression.

These findings lay the groundwork for further experimental validation in preclinical models and potentially for clinical translation.

13. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies significant cell-cell interactions (CCIs) involving Intestinal Epithelial cells, T cells (CD4+ and CD8+), B cells, Macrophages, Fibroblasts, and Endothelial cells that are differentially active between "Adj_normal" and "Tumor" conditions in colon tissue. The results are visualized as a dot plot, where the size of the dot represents the statistical significance (-log10(p-value)) of the interaction, and the color intensity reflects the scaled interaction strength (mean expression of the ligand-receptor pair). The aim is to understand how cellular communication networks are altered in colon cancer and identify potential therapeutic targets.

Visual Summary

The dot plot clearly delineates two major patterns of cell-cell interactions, segregated by tissue condition:

1. Interactions Predominant in 'Adj_normal' (top-left blue box): A large cluster of strong and significant interactions (darker red, larger dots) is observed consistently across most "Adj_normal" samples. These interactions are largely diminished or absent in "Tumor" samples. Key interactions in this group often involve Intestinal Epithelial cells, Fibroblasts, and Endothelial cells, with contributions from T cells. Notable examples include ProstaglandinE2-PTGER4 signaling, COL14A1-integrin interactions, CD320-JAML, and TNFSF10-TNFRSF10 (TRAIL) signaling.
2. Interactions Predominant in 'Tumor' (bottom-right blue box): Conversely, a distinct set of interactions is highly active and significant in "Tumor" samples, with minimal activity in "Adj_normal" samples. This pattern indicates specific communicative changes within the tumor microenvironment. These interactions frequently involve various collagen-integrin pairs, SPP1-integrin, CXCL12-CXCR4, and VEGFA-VEGFR signaling, often mediated by Fibroblasts, Endothelial cells, and Macrophages interacting with Intestinal Epithelial cells.

This differential pattern underscores a profound rewiring of cellular communication as normal colon tissue transitions into a cancerous state, reflecting both a loss of normal homeostatic signaling and the emergence of tumor-promoting interactions.

Biological Interpretation

Interactions Predominant in 'Adj_normal'

The interactions enriched in adjacent normal tissue likely represent crucial pathways for maintaining tissue homeostasis, normal immune surveillance, and epithelial integrity, whose disruption may contribute to tumor initiation or progression.

• ProstaglandinE2\_byPTGES2 - PTGER4 (Prostaglandin E2 - EP4 receptor) Signaling: This widespread interaction, involving various cell types including Intestinal Epithelial cells, Fibroblasts, and Endothelial cells, is essential for regulating inflammation, tissue repair, and maintaining epithelial barrier function in healthy tissue. Its reduction in tumor could reflect altered inflammatory responses and impaired tissue homeostasis.
• PubMed search for "Prostaglandin E2 colon homeostasis"
• COL14A1 - integrin\_a1b1\_complex: Collagen XIV (COL14A1) is a component of the extracellular matrix (ECM) and its interaction with integrin complexes, particularly involving Fibroblasts and Epithelial cells, suggests a role in maintaining the structural integrity and normal cell-matrix communication of healthy colon.
• GeneCards: COL14A1
• CD320 - JAML: This interaction, observed between Intestinal Epithelial cells and Endothelial cells, is involved in cell adhesion and inflammatory responses. Its presence in normal tissue indicates a role in maintaining cell-cell contacts and immune cell trafficking in a healthy state.
• GeneCards: CD320
• TNFSF10 - TNFRSF10D (TRAIL - TRAIL-R4) and TNFSF10 - TNFRSF10B (TRAIL - TRAIL-R2/DR5) Signaling: These interactions, particularly from T CD4+ and T CD8+ cells to Intestinal Epithelial cells, represent immune surveillance mechanisms. TRAIL (TNF-related apoptosis-inducing ligand) can induce apoptosis in cancer cells, and its strong presence in normal tissue implies a healthy immune environment. Its diminished presence in tumor samples might indicate an immune evasion strategy by cancer cells.
• PubMed search for "TRAIL colon cancer immune evasion"
• BMP4 - BMPR1A\_BMPR1B (Bone Morphogenetic Protein 4 - BMP Receptors): The interaction between Fibroblasts and Intestinal Epithelial cells involving BMP4 is critical for intestinal epithelial differentiation, proliferation, and maintaining crypt architecture. Its reduction could contribute to epithelial dysregulation and loss of differentiation in cancer.
• GeneCards: BMP4

Interactions Predominant in 'Tumor'

The interactions highly active in tumor samples highlight critical pathways driving tumor growth, invasion, angiogenesis, and immune modulation within the tumor microenvironment (TME).

• Collagen - Integrin Complexes (e.g., COL1A1/COL3A1/COL4A1/COL5A1/COL6A3 - integrin\_a1b1\_complex): These represent a significant upregulation of cell-extracellular matrix interactions, predominantly involving Fibroblasts (Cancer-Associated Fibroblasts, CAFs), Intestinal Epithelial cells, and Endothelial cells. CAFs are major producers of ECM components like collagens, and increased collagen deposition and cross-linking promote tumor stiffness, invasion, and metastasis by activating integrin signaling pathways that regulate cell survival, proliferation, and migration.
• PubMed search for "collagen integrin colorectal cancer"
• SPP1 - integrin\_a4b1\_complex/integrin\_a9b1\_complex (Osteopontin - Integrin): Osteopontin (SPP1), a matricellular protein produced by Macrophages and Intestinal Epithelial cells, is strongly interacting with integrins, particularly on Fibroblasts and Epithelial cells. SPP1 is a key mediator of inflammation, tissue remodeling, and cancer progression, promoting tumor cell survival, migration, and angiogenesis.
• GeneCards: SPP1
• CXCL12 - CXCR4 Axis: This crucial chemokine signaling pathway is highly active, predominantly involving Fibroblasts, Endothelial cells, and T cells. The CXCL12-CXCR4 axis plays a significant role in recruiting immune cells, stromal cells, and cancer cells, driving tumor angiogenesis, growth, and metastasis. CAFs are known sources of CXCL12.
• GeneCards: CXCL12
• GeneCards: CXCR4
• VEGFA - FLT1/KDR/NRP1 (VEGF-A - VEGFR1/VEGFR2/Neuropilin-1): These interactions, primarily between Endothelial cells and with Macrophages, are central to tumor angiogenesis, the formation of new blood vessels essential for supplying nutrients and oxygen to the rapidly growing tumor.
• GeneCards: VEGFA
• PGF - NRP2 (Placental Growth Factor - Neuropilin-2): PGF, an angiogenic factor, interacts with NRP2, notably within Endothelial cell populations and with Macrophages and Fibroblasts. This axis contributes to pathological angiogenesis in the tumor microenvironment.
• GeneCards: PGF
• WNT2B - SFRP1: The Wnt signaling pathway is frequently dysregulated in colorectal cancer. WNT2B, secreted by Fibroblasts, interacting with SFRP1 on Intestinal Epithelial cells could represent complex Wnt pathway modulation within the tumor, impacting epithelial cell proliferation and differentiation.
• GeneCards: WNT2B
• THBS1 - CD36 (Thrombospondin-1 - CD36): THBS1, a matricellular protein produced by Fibroblasts and Epithelial cells, interacts with CD36 on Macrophages. This interaction can modulate angiogenesis, immune cell function, and lipid metabolism, playing context-dependent roles in tumor progression.
• GeneCards: THBS1

Clinical or Translational Implications

The profound shift in cell-cell communication patterns observed in colon cancer tissues provides several avenues for therapeutic intervention and biomarker development.

Therapeutic Target Potential

• Targeting ECM Remodeling and Integrin Signaling: The widespread upregulation of collagen-integrin interactions and SPP1-integrin signaling in tumor tissue makes this axis an attractive therapeutic target. Inhibiting specific integrins (e.g., αvβ3, α5β1) or targeting the mechanisms of ECM deposition and remodeling (e.g., through inhibitors of lysyl oxidases) could disrupt tumor cell adhesion, migration, and invasion.
• Therapeutic Agents: Integrin antagonists (e.g., cilengitide, although with mixed clinical success, next-generation compounds or combination therapies are being explored). Antibodies targeting specific integrin subunits.
• Blocking the CXCL12-CXCR4 Axis: Given its prominent role in tumor growth, angiogenesis, and metastasis, targeting CXCR4 is a promising strategy. Inhibiting this pathway could hinder tumor cell dissemination and enhance the efficacy of other therapies.
• Therapeutic Agents: Plerixafor (a CXCR4 antagonist, currently used for stem cell mobilization, in trials for various cancers). Other small molecule CXCR4 inhibitors or anti-CXCR4 antibodies.
• Inhibiting Angiogenesis (VEGFA-VEGFR and PGF-NRP2): The strong presence of VEGFA-VEGFR and PGF-NRP2 interactions confirms angiogenesis as a crucial hallmark of colon cancer. Anti-angiogenic therapies are already part of standard care for metastatic colorectal cancer.
• Therapeutic Agents: Bevacizumab (anti-VEGFA monoclonal antibody), Ramucirumab (anti-VEGFR2 antibody), and multi-targeted tyrosine kinase inhibitors (e.g., Regorafenib, Sorafenib) that inhibit VEGFRs. Targeting NRP2 could also be explored.
• Modulating Prostaglandin E2 Signaling: The decrease in ProstaglandinE2-PTGER4 signaling in tumor suggests a disruption of normal tissue function. While NSAIDs broadly inhibit prostaglandin synthesis, specific EP4 receptor antagonists could be explored to restore normal anti-inflammatory or anti-tumor immune responses, or to prevent tumor-promoting effects of PGE2 in other contexts.
• Therapeutic Agents: EP4 receptor antagonists (in clinical development for various indications, including cancer).
• Reactivating TRAIL-mediated Apoptosis: The diminished TNFSF10 (TRAIL) signaling from T cells to Intestinal Epithelial cells in tumor could be a mechanism of immune evasion. Strategies to restore or enhance TRAIL-mediated apoptosis, potentially through recombinant TRAIL or TRAIL receptor agonists, might be beneficial, especially in combination with agents that sensitize cancer cells to apoptosis.
• Therapeutic Agents: Recombinant TRAIL or agonistic antibodies targeting TRAIL receptors (e.g., DR4/DR5), though challenges in clinical translation remain.

Biomarker Potential

The specific patterns of gain or loss of CCIs could serve as valuable biomarkers for colon cancer:

• Diagnostic/Prognostic Markers: The presence of specific tumor-enriched CCIs (e.g., high levels of CXCL12-CXCR4 or specific collagen-integrin interactions) could indicate cancer presence or aggressive disease. Conversely, the loss of normal tissue-enriched CCIs could also signal pathology.
• Predictive Markers for Therapy Response: High baseline activity of pathways like VEGFA-VEGFR could predict response to anti-angiogenic therapies. Similarly, the activity of the CXCL12-CXCR4 axis might predict response to CXCR4 inhibitors or guide combination therapies.

14. Condition-Specific Cell-Cell Interaction Patterns in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies cell-cell interactions (CCIs) involving selected immune checkpoint and cell cycle pathway genes across different cell types (Intestinal Epithelial cells, T cells, B cells, Macrophages, Fibroblasts, and Endothelial cells) in colon tissue. The results are presented as a dot plot showing condition-specific CCI patterns, comparing 'Adj_normal' and 'Tumor' samples. The strength of interaction is indicated by dot color (scaled log strength), and statistical significance by dot size (-log10(p-value)). This approach aims to elucidate how cellular communication networks, particularly those relevant to immune regulation and cell proliferation, are altered in the tumor microenvironment.

Visual Summary

The dot plot clearly segregates cell-cell interaction patterns between 'Adj_normal' and 'Tumor' conditions.

• Distinct Interaction Landscapes: There is a striking difference in the most significant and strongest interactions between the 'Adj_normal' and 'Tumor' samples. Interactions prominent in 'Adj_normal' samples (top-left quadrant) are largely absent or significantly weaker in 'Tumor' samples, and vice versa for 'Tumor'-specific interactions (bottom-right quadrant).
• 'Adj_normal' Condition: This condition shows a prevalence of interactions involving Diploid Intestinal Epithelial cells (Ent.Epi (Dipl)), Fibroblasts, Endothelial cells, T cells (CD4+, CD8+), and B cells. Key interaction types include AREG-EGFR, HBEGF-EGFR, TGFB1-TGFBR3, TGFB1-TGFbeta_receptor2, and IFNG-IFNGR1, many exhibiting strong signals (dark red, large dots) across multiple normal samples.
• 'Tumor' Condition: This condition displays a profound shift towards interactions involving Aneuploid Intestinal Epithelial cells (Ent.Epi (Aneupl)), which are characteristic of tumor cells. The 'Tumor' microenvironment is dominated by strong and significant interactions between Aneuploid Intestinal Epithelial cells, Fibroblasts, Macrophages, and Endothelial cells, often with T cells.
• Prominent Immune Checkpoint Activation: The interaction CD274_PDCD1 -- Mac | T CD8+ (PD-L1 from Macrophages to PD-1 on CD8+ T cells) is highly significant and strong across numerous tumor samples, suggesting active immune suppression. Similar interactions involving CD274 (PD-L1) are observed from Endothelial cells and Aneuploid Intestinal Epithelial cells to PDCD1 (PD-1) on T cells.
• Upregulation of Growth Factor and TGF-beta Signaling: Interactions such as AREG_EGFR -- Ent.Epi (Aneupl) | Fib, HBEGF_EGFR -- Ent.Epi (Aneupl) | Fib, and multiple TGFB1_TGFbeta_receptor and TGFB3_TGFbeta_receptor interactions (involving Aneuploid Intestinal Epithelial cells, Fibroblasts, Macrophages, and Endothelial cells) are highly active in tumor samples.
• Integrin-Mediated Signaling: Interactions involving TGFB1_integrin_avB6_complex and TGFB1_integrin_avB8_complex (e.g., between Aneuploid Intestinal Epithelial cells and Fibroblasts/Macrophages) are also notable in the tumor context.
• Sample Heterogeneity: Within both 'Adj_normal' and 'Tumor' conditions, there is some variability in the strength and presence of specific CCIs across different samples, though general patterns hold true for the majority.

Biological Interpretation

The observed shifts in cell-cell interactions provide critical insights into the biological processes driving colon tumorigenesis and shaping the tumor microenvironment (TME).

1. Immune Evasion via PD-1/PD-L1 Axis: The strong and prevalent CD274_PDCD1 -- Mac | T CD8+ interaction in tumor samples is a hallmark of immune evasion. Tumor-associated macrophages (TAMs) expressing PD-L1 (CD274) engage PD-1 (PDCD1) on cytotoxic T lymphocytes (CD8+ T cells), leading to T cell exhaustion and suppression of anti-tumor immunity. This allows tumor cells, identified here as Aneuploid Intestinal Epithelial cells, to escape immune surveillance. This mechanism is well-documented in colorectal cancer.

• Associated Signaling Pathways/Mechanisms: The PD-1/PD-L1 axis transmits inhibitory signals that downregulate T cell receptor signaling, impair cytokine production (e.g., IFN-γ), and promote T cell anergy or apoptosis. GeneCards: CD274, GeneCards: PDCD1

2. TGF-beta Signaling in TME Remodeling: The widespread activation of TGFB1/3-TGFbeta_receptor interactions across various cell types (Aneuploid Intestinal Epithelial cells, Fibroblasts, Macrophages, Endothelial cells, T cells) in the tumor context underscores the central role of TGF-beta in orchestrating the pro-tumorigenic TME. TGF-beta promotes epithelial-mesenchymal transition (EMT) in tumor cells, drives fibroblast activation (leading to cancer-associated fibroblasts, CAFs), induces angiogenesis, and suppresses anti-tumor immune responses.

• Associated Signaling Pathways/Mechanisms: TGF-beta binding to its receptor complex (comprising Type I (TGFBR1) and Type II (TGFBR2) receptors) leads to phosphorylation of SMAD proteins (e.g., SMAD2/3), which then translocate to the nucleus to regulate gene expression involved in cell proliferation, differentiation, apoptosis, and extracellular matrix production. GeneCards: TGFB1, GeneCards: TGFBR1

3. EGFR-Mediated Tumor Growth: Elevated AREG-EGFR and HBEGF-EGFR interactions, particularly involving Aneuploid Intestinal Epithelial cells and Fibroblasts, indicate active growth factor signaling. EGFR signaling pathways (RAS/MAPK, PI3K/AKT) are critical for promoting tumor cell proliferation, survival, migration, and angiogenesis.

• Associated Signaling Pathways/Mechanisms: Ligand binding to EGFR activates its intrinsic tyrosine kinase activity, leading to autophosphorylation and recruitment of adapter proteins. This initiates a cascade of intracellular signaling pathways, including the MAPK/ERK pathway (promoting cell proliferation) and the PI3K/AKT pathway (promoting cell survival and growth). GeneCards: AREG, GeneCards: EGFR

4. Reprogramming of Stromal-Tumor Interactions: The shift from 'Adj_normal' to 'Tumor' shows a significant reorganization of how Intestinal Epithelial cells (now aneuploid tumor cells), Fibroblasts, Endothelial cells, and various immune cells communicate. This indicates a complex and integrated network supporting tumor progression, rather than isolated changes. The prominent involvement of fibroblasts and endothelial cells confirms their role as key components of the reactive stromal microenvironment in colon cancer.
5. Role of Aneuploid Intestinal Epithelial Cells: The consistent presence of "Ent.Epi (Aneupl)" as a central player in most strong tumor-specific interactions strongly supports their malignant nature and their active role in shaping the pro-tumorigenic microenvironment.

Clinical or Translational Implications

The identified condition-specific cell-cell interactions offer promising avenues for therapeutic intervention in colon cancer.

1. Immune Checkpoint Blockade for Colon Cancer:

• Potential as Therapeutic Target: The robust CD274 (PD-L1) – PDCD1 (PD-1) interaction in tumor samples strongly indicates that immune checkpoint inhibitors (ICIs) are relevant therapeutic strategies. By blocking this inhibitory axis, ICIs aim to restore the anti-tumor function of CD8+ T cells. This is particularly relevant for colon cancer patients with microsatellite instability-high (MSI-H) tumors, which often respond well to ICIs.
• Relevant Therapeutic Agents: Anti-PD-1 antibodies such as Nivolumab and Pembrolizumab, and anti-PD-L1 antibodies such as Atezolizumab, Durvalumab, and Avelumab are approved for various cancers, including certain subsets of colorectal cancer. PubMed search: PD-1 PD-L1 colon cancer immunotherapy

2. Targeting TGF-beta Signaling:

• Potential as Therapeutic Target: The widespread involvement of TGF-beta signaling in the tumor microenvironment makes it a high-priority target. Inhibiting this pathway could mitigate immune suppression, reduce EMT, and impair TME remodeling that supports tumor growth and metastasis.
• Relevant Therapeutic Agents: Small molecule inhibitors of TGFBR1 (e.g., Galunisertib, Vactosertib) and neutralizing antibodies against TGF-beta ligands are currently undergoing clinical evaluation for various solid tumors. PubMed search: TGF-beta inhibitor cancer therapy

3. EGFR Inhibition in Colon Cancer:

• Potential as Therapeutic Target: The prominent AREG-EGFR and HBEGF-EGFR interactions reinforce EGFR as a critical driver of tumor cell proliferation and survival. Targeting EGFR is a well-established strategy in colorectal cancer, particularly in RAS wild-type tumors.
• Relevant Therapeutic Agents: Monoclonal antibodies such as Cetuximab and Panitumumab, which block ligand binding to EGFR, are commonly used in metastatic colorectal cancer. Small molecule tyrosine kinase inhibitors (TKIs) like Erlotinib are also available, though less commonly used for colon cancer without specific mutations. PubMed search: EGFR inhibitor colon cancer

4. Combination Therapies: Given the complexity and interplay of these pathways, combining therapies that target different aspects of the TME (e.g., immune checkpoints, growth factor signaling, and TME remodeling) could yield more durable and effective responses for colon cancer patients. For instance, combining anti-PD-1/PD-L1 agents with TGF-beta pathway inhibitors is an active area of research to overcome resistance to immunotherapy.

15. Surfaceome Marker Expression in Intestinal Epithelial Cells of Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression profiles of surfaceome markers in Intestinal Epithelial cells, comparing "Adj_normal" (adjacent normal tissue) and "Tumor" conditions within the colon. The purpose is to identify differentially expressed surface markers that could serve as diagnostic, prognostic, or therapeutic targets in colon cancer. The markers were selected based on one-vs-rest differential expression analysis (considering non-zero percentage score and fold change) and restricted to surfaceome proteins. The plot differentiates between individual patient samples and also notes the ploidy status for tumor samples where available.

Visual Summary

The dot plot effectively visualizes the expression of 60 surfaceome markers across various patient samples categorized by condition ("Adj_normal" and "Tumor"). The size of each dot represents the fraction of cells expressing the marker within that sample group, while the color intensity indicates the mean expression level.

Key observations from the plot include:

• Distinct Expression Profiles: There is a clear segregation of marker expression patterns between Adj_normal and Tumor Intestinal Epithelial cells.
• Adj_normal Specific Markers: A cluster of markers, prominently including PIGR, VSIG2, GPA33, CA12, LYPD8, and MUC4, shows high expression (large, dark red dots) across most Adj_normal samples. These markers are largely absent or expressed at very low levels in tumor samples.
• Tumor-Associated Markers: In contrast, a broad panel of markers, such as CEACAM5, CEACAM6, CD44, EPCAM, CDH17, SLC1A5, HBEGF, DDR1, ITGA6, ITGB1, MUC3A, and others, demonstrates significantly higher expression (large, dark red dots) in many tumor samples. These markers are mostly low or undetectable in Adj_normal samples.
• Intra-Tumor Heterogeneity: While many markers show general upregulation in tumor samples, there is some variability in expression levels and fraction of expressing cells across different tumor samples (e.g., some tumor samples might express certain markers at lower levels than others, or in a smaller fraction of cells), hinting at inter-patient or intra-tumor heterogeneity.
• Ploidy-Associated Patterns: The plot labels indicate 'Diploid SMC-T' and 'SMC-T' (often representing aneuploid cells in this context, consistent with 'Resolved tumor-origin cell type: Intestinal Epithelial cell' and 'Aneuploid: 14240 (22.4%)' in the data context). The strong upregulation of tumor-associated markers is predominantly observed in the non-Diploid Tumor samples (bottom block of tumor samples), suggesting that many of these oncogenic surface markers are enriched in aneuploid, potentially more aggressive, tumor cells.

Biological Interpretation

The differential expression of surfaceome markers between adjacent normal colon epithelium and tumor cells provides crucial insights into the molecular changes occurring during colon cancer development and progression. Surface proteins are particularly attractive as therapeutic targets because they are readily accessible to antibody-based therapies or small molecule inhibitors.

Markers Predominantly Expressed in Adjacent Normal Intestinal Epithelial Cells

These markers often represent normal epithelial function or differentiation states that are lost or altered during oncogenesis. While not typically direct therapeutic targets for *cancer itself*, their loss can be indicative of malignant transformation, and some may have roles in normal tissue maintenance or could be leveraged in specific therapeutic approaches (e.g., targeted delivery to normal cells).

GPA33 (Glycoprotein A33)

• Signaling Pathways/Mechanisms: GPA33 is a transmembrane glycoprotein primarily expressed on the surface of normal intestinal epithelial cells and some colon cancers. While its precise physiological function is not fully elucidated, it is implicated in cell-cell adhesion and tissue architecture maintenance.
• Relevant Therapeutic Agents: GPA33 has been explored as a target for antibody-based therapies, particularly radioimmunotherapy in colorectal cancer. For instance, novel antibody-drug conjugates or radiolabeled antibodies targeting GPA33 are under investigation.
• Supporting Evidence: High expression in normal intestinal cells, but also present in a subset of colorectal cancers, making it a target for selective delivery. GeneCards: GPA33
• Therapeutic Target Status: Established Therapeutic Target (for specific radioimmunotherapy strategies in CRC).

PIGR (Polymeric Immunoglobulin Receptor)

• Signaling Pathways/Mechanisms: PIGR is a transmembrane glycoprotein expressed by epithelial cells, primarily involved in the transcytosis of polymeric immunoglobulins (IgA and IgM) from the lamina propria across the epithelial layer into the lumen, contributing to mucosal immunity.
• Relevant Therapeutic Agents: PIGR is not typically a direct therapeutic target for cancer. Its downregulation in tumor cells often signifies a loss of epithelial differentiation, which could be exploited indirectly (e.g., as a marker for loss of normal function).
• Supporting Evidence: Constitutively expressed in normal secretory epithelial cells. Its absence in tumors may correlate with poorer differentiation and aggressive behavior. GeneCards: PIGR
• Therapeutic Target Status: Less Well-Characterized Marker with Potential (primarily as a marker of normal epithelium or differentiation status, not a direct oncogenic driver target).

Markers Predominantly Expressed in Tumor Intestinal Epithelial Cells

These markers represent opportunities for targeted therapies due to their elevated expression in malignant cells and accessibility on the cell surface.

• CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 5)
• Signaling Pathways/Mechanisms: CEACAM5 is a cell adhesion molecule belonging to the immunoglobulin superfamily. It plays roles in cell adhesion, proliferation, differentiation, and immune modulation. In cancer, it can promote tumor cell survival, migration, and metastasis, and suppress anti-tumor immunity.
• Relevant Therapeutic Agents: CEACAM5 is a well-established tumor marker (Carcinoembryonic Antigen, CEA) used for diagnosis and monitoring of various cancers, including colorectal cancer. It is also an active target for therapeutic antibodies, including antibody-drug conjugates (ADCs) like tusamitamab ravtansine, which have shown promise in clinical trials.
• Supporting Evidence: High expression in CRC is associated with poor prognosis and advanced disease. GeneCards: CEACAM5, PubMed: CEACAM5 in colon cancer therapy
• Therapeutic Target Status: Established Therapeutic Target.

EPCAM (Epithelial Cell Adhesion Molecule)

• Signaling Pathways/Mechanisms: EPCAM is a transmembrane glycoprotein involved in cell-cell adhesion, proliferation, differentiation, and migration. It can function as an oncogene by activating Wnt signaling pathways and promoting epithelial-mesenchymal transition (EMT), thus contributing to tumor growth and metastasis.
• Relevant Therapeutic Agents: EPCAM has been a target for various immunotherapeutic strategies, including bispecific antibodies (e.g., catumaxomab for malignant ascites, though withdrawn for commercial reasons) and CAR-T cell therapies, particularly in epithelial cancers.
• Supporting Evidence: Widely overexpressed in epithelial cancers, including CRC, and associated with cancer stem cell properties. GeneCards: EPCAM, PubMed: EPCAM in colon cancer therapy
• Therapeutic Target Status: Established Therapeutic Target (though specific agents may have complex clinical histories).

CD44 (CD44 Molecule)

• Signaling Pathways/Mechanisms: CD44 is a polymorphic transmembrane glycoprotein that acts as a primary receptor for hyaluronan and interacts with various other ligands, including osteopontin and growth factors. It plays critical roles in cell adhesion, migration, proliferation, and survival, and is often implicated in cancer stem cell biology, epithelial-mesenchymal transition, and metastasis. It can activate signaling pathways like PI3K/Akt and MAPK/ERK.
• Relevant Therapeutic Agents: CD44 is a promising therapeutic target, especially due to its association with cancer stem cells and drug resistance. Investigational agents include antibodies and small molecules designed to disrupt CD44-hyaluronan interactions.
• Supporting Evidence: Overexpression of CD44 variants (e.g., CD44v6) is linked to poor prognosis and metastatic potential in CRC. GeneCards: CD44
• Therapeutic Target Status: Less Well-Characterized Marker with Potential as a Therapeutic Target.

CDH17 (Cadherin 17)

• Signaling Pathways/Mechanisms: CDH17, also known as LI-cadherin, is an atypical cadherin involved in calcium-dependent cell-cell adhesion. It is highly expressed in gastrointestinal epithelia. In cancer, CDH17 contributes to increased cell motility, invasion, and metastatic potential, and may regulate Wnt/β-catenin signaling.
• Relevant Therapeutic Agents: CDH17 is an emerging target for antibody-drug conjugates (ADCs) in gastrointestinal cancers due to its high and specific expression in malignant cells.
• Supporting Evidence: Aberrant expression of CDH17 is frequently observed in gastric and colorectal cancers, correlating with advanced disease and poor outcomes. GeneCards: CDH17
• Therapeutic Target Status: Less Well-Characterized Marker with Potential as a Therapeutic Target.

SLC1A5 (Solute Carrier Family 1 Member 5) / ASCT2

• Signaling Pathways/Mechanisms: SLC1A5 is a sodium-dependent neutral amino acid transporter, critical for the cellular uptake of glutamine. Glutamine is a vital nutrient for rapidly proliferating cancer cells, fueling anabolic pathways, nucleotide synthesis, and maintaining redox balance. Upregulation of SLC1A5 enhances glutamine metabolism, supporting tumor growth.
• Relevant Therapeutic Agents: Inhibition of glutamine metabolism is an active area of cancer therapy research. SLC1A5 inhibitors are under development to block glutamine uptake, alongside glutaminase inhibitors that target glutamine catabolism.
• Supporting Evidence: Increased SLC1A5 expression is frequently observed in various cancers, including CRC, linking directly to tumor cell proliferation and survival. GeneCards: SLC1A5, PubMed: ASCT2 colon cancer therapy
• Therapeutic Target Status: Less Well-Characterized Marker with Potential as a Therapeutic Target.

HBEGF (Heparin-binding EGF-like Growth Factor)

• Signaling Pathways/Mechanisms: HBEGF is a member of the epidermal growth factor (EGF) family, acting as a potent mitogen and chemotactic factor. It binds to and activates EGFR (ERBB1) and ERBB4, initiating downstream signaling cascades such as MAPK/ERK and PI3K/Akt, which promote cell proliferation, survival, angiogenesis, and invasion.
• Relevant Therapeutic Agents: While EGFR itself is a well-established therapeutic target (e.g., Cetuximab, Panitumumab in CRC), HBEGF overexpression can drive EGFR activation, sometimes contributing to resistance to EGFR inhibitors. Specific HBEGF-blocking antibodies are being investigated.
• Supporting Evidence: Overexpression of HBEGF is frequently observed in various cancers, including CRC, and is associated with tumor progression and metastasis. GeneCards: HBEGF
• Therapeutic Target Status: Less Well-Characterized Marker with Potential as a Therapeutic Target (as a ligand regulating a key oncogenic pathway).

DDR1 (Discoidin Domain Receptor Tyrosine Kinase 1)

• Signaling Pathways/Mechanisms: DDR1 is a receptor tyrosine kinase uniquely activated by collagen. Upon binding to collagen, DDR1 initiates intracellular signaling cascades, including MAPK, PI3K/Akt, and Src family kinases, influencing cell adhesion, proliferation, migration, invasion, and differentiation. It plays a significant role in tumor-stroma interactions.
• Relevant Therapeutic Agents: Due to its role in tumor invasion and metastasis, DDR1 is considered a promising target. Small molecule inhibitors specifically targeting DDR1 kinase activity are currently under preclinical investigation.
• Supporting Evidence: Elevated DDR1 expression is observed in various human cancers, including CRC, and is linked to aggressive phenotypes and metastatic spread. GeneCards: DDR1
• Therapeutic Target Status: Less Well-Characterized Marker with Potential as a Therapeutic Target.

Clinical or Translational Implications

The identification of these differentially expressed surfaceome markers holds significant clinical and translational implications for colon cancer:

1. Diagnostic and Prognostic Biomarkers: Markers like CEACAM5 and EPCAM are already utilized in clinical practice or have strong evidence as diagnostic/prognostic indicators. The observed upregulation of these and other markers (e.g., CD44, CDH17) in tumor cells, particularly in aneuploid tumor populations, reinforces their potential for early detection, monitoring disease progression, and predicting patient outcomes.
2. Therapeutic Targets:

• Established Targets: The high expression of established targets like CEACAM5 and EPCAM in tumor Intestinal Epithelial cells confirms their continued relevance for current and emerging immunotherapies, including antibody-drug conjugates (ADCs) and CAR-T cell approaches. GPA33, while also expressed in normal tissue, represents a validated target for radioimmunotherapy strategies.
• Potential New Targets: Markers such as CD44, CDH17, SLC1A5, HBEGF, and DDR1, which show robust upregulation in tumor cells, represent promising candidates for the development of novel targeted therapies. Targeting these proteins could lead to new ADCs, bispecific antibodies, or small molecule inhibitors that specifically disrupt tumor growth, metabolism, or metastasis with potentially fewer off-target effects.

3. Targeting Cancer Cell Metabolism: The upregulation of SLC1A5 (ASCT2), a glutamine transporter, highlights the metabolic rewiring in tumor cells. Targeting glutamine uptake or metabolism could be a viable therapeutic strategy, potentially synergistic with other treatments.
4. Addressing Tumor Heterogeneity: The observation of varying marker expression across different tumor samples underscores the need for patient-specific or subtype-specific therapeutic approaches. Combination therapies targeting multiple surface markers or their downstream pathways might be necessary to overcome heterogeneity and prevent resistance.

Overall, this analysis provides a valuable molecular map of the Intestinal Epithelial cell surface in colon cancer, guiding further investigation into the functional roles of these markers and their validation as next-generation therapeutic targets.

16. Macrophage Condition-Specific Surfaceome Marker Analysis in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for Macrophages across "Adj_normal" and "Tumor" colon tissue samples, derived from single-cell RNA-seq data. The goal was to identify surface markers with differential expression patterns that could inform macrophage phenotype, function within the tumor microenvironment (TME), and potential therapeutic targets. Markers were identified using a one-vs-rest comparison, applying stringent cutoffs for non-zero percentage score and fold change (Adj_normal_vs_others: nz_pct_score ≥ 0.117, nz_pct FC > 1.25; Tumor_vs_others: nz_pct_score ≥ 0.183, nz_pct FC > 1.25), and were restricted to surfaceome genes.

Visual Summary

The dot plot clearly illustrates a robust distinction in surface marker expression profiles between Macrophages in "Adj_normal" and "Tumor" colon tissue samples.

• Condition-Specific Clustering: Markers are distinctly grouped, with those predominantly expressed in "Adj_normal" samples on the left side of the plot and those specific to "Tumor" samples on the right. This indicates a significant phenotypic shift in macrophages in the tumor microenvironment.
• Adj_normal Macrophage Markers: Samples from adjacent normal tissue (e.g., SMC01-N, SMC10-N) show high mean expression (darker red dots) and prevalence (larger dot size) for markers such as *HLA-DMB*, *HLA-DOA2*, *MS4A6A*, *MRC1*, *CSF1R*, and *FOLR2*. These markers are largely absent or expressed at very low levels in tumor macrophages.
• Tumor Macrophage Markers: Conversely, macrophages from tumor samples (e.g., SMC10-T, SMC21-T) exhibit strong and widespread expression of a distinct set of markers including *FCGR3A*, *GPNMB*, *TREM1*, *TREM2*, *MMP14*, *ANPEP*, *CD40*, *IL10RB*, and *FCGR1A*. These markers are scarcely expressed in adjacent normal tissue macrophages.
• Heterogeneity within Conditions: While clear patterns emerge, there is also some heterogeneity in expression levels and fractions of expressing cells across individual samples within the "Tumor" condition, suggesting diverse macrophage subsets or activation states even within the TME.
• Cell Counts: The bar plot on the right confirms that a sufficient number of cells are present in most samples to reliably assess marker expression.

Biological Interpretation

The distinct sets of surface markers highlight significant phenotypic differences between macrophages in normal colon tissue and those infiltrating colon tumors. This reflects their divergent roles in maintaining tissue homeostasis versus promoting tumor progression.

Markers Enriched in Adj_normal Macrophages

These markers typically suggest a homeostatic, antigen-presenting, or M2-like phenotype involved in normal tissue maintenance or early, regulated immune responses.

1. HLA-DMB & HLA-DOA2 (MHC Class II Components)

• Associated Signaling Pathways: Antigen presentation pathway to CD4+ T cells. They are chaperones crucial for peptide loading onto MHC class II molecules.
• Role in TME (Colon Cancer): Their high expression in normal macrophages suggests an active role in immune surveillance and initiating adaptive immune responses by presenting antigens. Downregulation in tumor macrophages might contribute to immune evasion by impairing antigen presentation.
• Potential as Therapeutic Target: While not direct therapeutic targets themselves, maintaining or enhancing MHC class II expression on antigen-presenting cells in the TME is a goal of some immunotherapies to restore anti-tumor immunity.
• Relevant Therapeutic Agents: Immunomodulatory drugs aiming to enhance antigen presentation pathways.
• Other Information: These genes are fundamental to the adaptive immune system's recognition of foreign antigens.
• Reference: PubMed search: MHC Class II antigen presentation macrophage cancer

2. MRC1 (CD206)

• Associated Signaling Pathways: Endocytosis, phagocytosis, innate immune recognition via C-type lectin receptor signaling.
• Role in TME (Colon Cancer): CD206 is a well-established marker for alternatively activated (M2-like) macrophages, which are often involved in wound healing, tissue repair, and immune suppression. Its higher expression in adjacent normal tissue could reflect a baseline homeostatic M2-like phenotype in the healthy gut, which maintains tissue integrity. In the tumor context, M2-like macrophages are generally pro-tumorigenic.
• Potential as Therapeutic Target: CD206+ macrophages can be targeted for depletion or drug delivery vehicles using specific antibodies or ligands, especially if they are identified as harmful M2 subsets in other contexts.
• Relevant Therapeutic Agents: Antibody-drug conjugates (ADCs) or liposomal drug delivery systems engineered to bind CD206.
• Reference: GeneCards: MRC1

3. CSF1R (Colony Stimulating Factor 1 Receptor)

• Associated Signaling Pathways: CSF1-CSF1R signaling pathway, critical for macrophage survival, proliferation, differentiation, and chemotaxis, involving tyrosine kinase signaling cascades.
• Role in TME (Colon Cancer): CSF1R signaling is essential for the recruitment, survival, and differentiation of macrophages, including tumor-associated macrophages (TAMs). Its presence in normal tissue macrophages indicates their essential role in homeostasis. While often associated with TAM recruitment and survival in tumors, its relatively higher expression in adjacent normal tissue here might highlight a basal requirement for macrophage maintenance.
• Potential as Therapeutic Target: CSF1R is a major therapeutic target in cancer. Inhibiting CSF1R can reduce TAM numbers and reprogram their phenotype, thereby suppressing tumor growth and metastasis.
• Relevant Therapeutic Agents: Small molecule CSF1R inhibitors (e.g., pexidartinib, cabiralizumab) are in clinical trials for various cancers, including those where TAMs are prominent.
• Reference: PubMed search: CSF1R inhibitors cancer therapy

Markers Enriched in Tumor Macrophages

These markers often point towards pro-tumorigenic, immunosuppressive, or highly activated macrophage phenotypes that contribute to tumor growth, invasion, and immune evasion.

1. FCGR3A (CD16A) & FCGR1A (CD64)

• Associated Signaling Pathways: Fc receptor signaling pathways, involved in antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and immune complex clearance.
• Role in TME (Colon Cancer): Fc receptors on macrophages allow them to bind antibody-opsonized cells. CD16 (FCGR3A) is commonly found on NK cells and certain macrophage subsets, mediating ADCC. CD64 (FCGR1A) is a high-affinity Fc receptor, upregulated on activated macrophages, leading to enhanced phagocytosis and inflammatory responses. Their upregulation in tumor macrophages could suggest a context where these cells are actively engaged with immune complexes or attempting to clear cellular debris, or might be exploited by therapeutic antibodies.
• Potential as Therapeutic Target: These receptors are crucial for the efficacy of therapeutic antibodies through ADCC. Enhancing their expression or function on TAMs could boost anti-tumor antibody therapies.
• Relevant Therapeutic Agents: Monoclonal antibodies designed to induce ADCC, such as cetuximab (targeting EGFR in colon cancer).
• Reference: UniProt: FCGR3A, UniProt: FCGR1A

2. GPNMB (Glycoprotein Non-metastatic Melanoma Protein B)

• Associated Signaling Pathways: Involved in cell adhesion, migration, tumor progression, and immune modulation, often linked to lysosomal trafficking and autophagy pathways.
• Role in TME (Colon Cancer): GPNMB is frequently overexpressed in various cancers and on TAMs. It promotes tumor growth, invasion, and metastasis, and contributes to immune suppression. Its strong expression in tumor macrophages indicates a pro-tumorigenic role.
• Potential as Therapeutic Target: GPNMB is an attractive target for antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to GPNMB-expressing tumor cells and TAMs.
• Relevant Therapeutic Agents: An ADC targeting GPNMB, glembatumumab vedotin, has been investigated in clinical trials.
• Reference: UniProt: GPNMB

3. TREM1 & TREM2 (Triggering Receptor Expressed on Myeloid Cells)

• Associated Signaling Pathways: Both are receptors that modulate innate immune responses. TREM1 amplifies inflammatory signaling (e.g., TLR-induced pathways), while TREM2 is involved in phagocytosis, lipid sensing, and can promote M2-like immunosuppressive phenotypes.

Role in TME (Colon Cancer):

• TREM1: Its upregulation in tumor macrophages suggests an inflammatory environment, which can paradoxically contribute to tumor progression in some contexts.
• TREM2: Highly expressed on TAMs in many cancers, TREM2+ macrophages promote tumor growth, immune evasion, and resistance to therapy. It is a key marker for a distinct subset of immunosuppressive TAMs.
• Potential as Therapeutic Target: Modulating TREM1 or TREM2 signaling pathways is a growing area for cancer immunotherapy. Blocking TREM1 might reduce pro-tumorigenic inflammation, while targeting TREM2 (e.g., with antibodies or small molecules) could reprogram immunosuppressive TAMs.
• Relevant Therapeutic Agents: Inhibitors or activators of TREM pathways are in preclinical and early clinical development.
• Reference (TREM1): PubMed search: TREM1 cancer macrophage
• Reference (TREM2): UniProt: TREM2

4. MMP14 (Matrix Metalloproteinase 14)

• Associated Signaling Pathways: Extracellular matrix (ECM) degradation, cell migration, invasion, and angiogenesis. It is a membrane-anchored metalloproteinase.
• Role in TME (Colon Cancer): MMP14 expressed by TAMs is a key enzyme in remodeling the ECM, facilitating tumor cell invasion, metastasis, and angiogenesis. Its high expression underscores the role of tumor macrophages in promoting an invasive phenotype.
• Potential as Therapeutic Target: Inhibiting MMP14 could reduce tumor invasion and metastasis. While broad-spectrum MMP inhibitors have had limited clinical success due to side effects, more specific MMP14 inhibitors are being developed.
• Relevant Therapeutic Agents: Specific MMP14 inhibitors or strategies to block its enzymatic activity.
• Reference: GeneCards: MMP14

5. IL10RB (Interleukin 10 Receptor Subunit Beta)

• Associated Signaling Pathways: IL-10 signaling pathway, which is profoundly immunosuppressive. IL10RB is a common chain for receptors of IL-10, IL-22, and IL-26.
• Role in TME (Colon Cancer): High expression of IL10RB on tumor macrophages makes them highly responsive to IL-10, an immunosuppressive cytokine often abundant in the TME. This responsiveness leads to a suppressed anti-tumor immune response, promoting tumor growth and progression.
• Potential as Therapeutic Target: Blocking IL-10 signaling by targeting IL10RB could reverse macrophage-mediated immunosuppression in the TME, thereby enhancing anti-tumor immunity.
• Relevant Therapeutic Agents: Antibodies or small molecules designed to block IL10RB or neutralize IL-10 could be employed in combination with other immunotherapies.
• Reference: GeneCards: IL10RB

Clinical or Translational Implications

The identification of distinct macrophage surface marker profiles between adjacent normal tissue and colon tumors has several clinical and translational implications:

• Biomarker Development: The differentially expressed markers (e.g., *GPNMB*, *TREM2*, *MMP14*, *IL10RB* for tumor; *MRC1*, *CSF1R*, *FOLR2* for normal) could serve as diagnostic or prognostic biomarkers for colon cancer progression, potentially detectable in liquid biopsies or by imaging techniques that target these surface proteins.
• Therapeutic Targeting Strategies: The tumor-specific markers represent promising therapeutic targets.
• Direct targeting: ADCs against markers like GPNMB could deliver cytotoxic drugs specifically to pro-tumorigenic TAMs.
• Immunomodulation: Modulating receptors like TREM1/2 or IL10RB could reprogram TAMs from an immunosuppressive to an anti-tumor phenotype, enhancing the efficacy of existing immunotherapies (e.g., checkpoint inhibitors). Targeting CSF1R, identified in both normal and tumor contexts, remains a key strategy to deplete or reprogram TAMs.
• Combination Therapies: Combining therapies that target these macrophage-specific pathways with other modalities (e.g., chemotherapy, radiation, T-cell therapies) could offer synergistic benefits in colon cancer treatment.
• Patient Stratification: Understanding these macrophage phenotypes could help stratify patients based on their TME characteristics, enabling personalized treatment approaches. Patients with high expression of pro-tumorigenic macrophage markers might benefit more from TAM-targeting therapies.
• Experimental Validation: These identified markers provide excellent candidates for further experimental validation in preclinical models (e.g., organoids, xenografts, syngeneic models) and human tissue samples using techniques like multiplex immunofluorescence, flow cytometry, or spatial transcriptomics to confirm their spatial distribution, co-expression patterns, and functional significance in colon cancer.

17. Fibroblast Condition-Specific Surfaceome Markers in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed by Fibroblasts in human Colon tissue, comparing "Adj_normal" (adjacent normal) and "Tumor" conditions. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across different patient samples within each condition. This approach aims to uncover distinct molecular signatures of fibroblasts that contribute to the tumor microenvironment (TME) versus those in normal tissue, with a focus on potential therapeutic targets.

Visual Summary

The dot plot clearly segregates fibroblast markers into two distinct groups based on their expression profiles across the "Adj_normal" and "Tumor" conditions.

• Adj_normal Fibroblast Markers: A cluster of markers, including *PROCR*, *TFPI*, *APLP2*, *SCARA5*, *IL6ST*, *CD302*, *CADM3*, *PTCH1*, and *SEMA4A*, shows high expression (dark red circles) and high prevalence (large circles) exclusively in fibroblast populations from "Adj_normal" samples. These markers are largely absent or expressed at very low levels in "Tumor" samples.
• Tumor Fibroblast Markers: Conversely, a much larger and highly expressed set of markers characterizes fibroblasts from "Tumor" samples. Prominent markers in this group, such as *SEMA7A*, *ANTXR1*, *PLAUR*, *PDGFRB*, *RPN1*, *FAP*, *ITGAV*, *PMEPA1*, *CD276*, *SSR1*, *PDLIM5*, *ITGA5*, *PKP3*, *CD82*, *ITGB5*, *TMEM30A*, *GLIPR1*, *TMED7*, *NOTCH3*, *CLDN4*, *F2R*, *ITGA1*, *TMEM158*, *BACE2*, *EDNRA*, *ANKH*, and *ADAM19*, exhibit strong expression and high prevalence in "Tumor" samples, while being largely absent or lowly expressed in "Adj_normal" samples. This indicates a significant shift in the surface proteome of fibroblasts in the tumor microenvironment.
• Sample-level Variability: Within each condition, some heterogeneity is observed among samples. For instance, in "Adj_normal" samples, *CD302* shows lower prevalence in some samples (e.g., SMC08-N, SMC24-T - though the latter is technically a normal sample from a patient with tumor, grouped under Adj_normal for analysis) compared to others. Similarly, within "Tumor" samples, certain markers show slight variations in expression or prevalence across different patient-derived tumor samples.
• Cell Counts: The bar plot on the right indicates the number of fibroblast cells analyzed per sample, ranging from 33 to 542 cells, confirming sufficient cellular representation for robust marker identification.

Biological Interpretation

Fibroblasts play a critical role in shaping the tumor microenvironment (TME), transitioning from quiescent normal fibroblasts (NFs) to activated cancer-associated fibroblasts (CAFs) during tumor progression. This analysis highlights specific surface markers that delineate these different functional states in colon cancer.

Markers Enriched in Adjacent Normal Fibroblasts

Fibroblasts in adjacent normal tissue likely contribute to tissue homeostasis, wound healing, and structural support.

• PROCR (Protein C Receptor): Also known as EPCR, it is a receptor for activated protein C and is expressed on endothelial cells and mesenchymal stem cells. In normal fibroblasts, its expression might be related to maintaining tissue integrity and regulating inflammatory responses. It has roles in immune regulation and cell survival, and its loss in CAFs could indicate a shift towards a pro-inflammatory or pro-tumorigenic phenotype. GeneCards: PROCR
• TFPI (Tissue Factor Pathway Inhibitor): A Kunitz-type serine protease inhibitor primarily known for its role in regulating coagulation. Its expression in normal fibroblasts suggests a role in maintaining vascular integrity and preventing excessive coagulation in normal tissue.
• IL6ST (Interleukin 6 Signal Transducer): Also known as gp130, this is the common signal-transducing subunit of the IL-6 receptor family. Its presence in normal fibroblasts indicates responsiveness to various cytokines, including IL-6, which is involved in inflammation and tissue repair. While IL-6 signaling can be pro-tumorigenic, its basal activity in normal fibroblasts might be crucial for tissue maintenance. GeneCards: IL6ST
• CD302 (C-type Lectin Domain Family 13 Member A): A transmembrane glycoprotein, potentially involved in cell adhesion and immune response. Its role in normal fibroblasts is less characterized but could be related to cell-matrix interactions or immune surveillance in healthy tissue.
• CADM3 (Cell Adhesion Molecule 3): Belongs to the nectin-like family of adhesion molecules. Involved in cell-cell adhesion and neural cell interactions. In normal fibroblasts, it might contribute to the organized structure of connective tissue.
• PTCH1 (Patched 1): A receptor for Hedgehog signaling ligands, playing a critical role in embryonic development and adult tissue homeostasis. Its presence in normal fibroblasts suggests active Hedgehog signaling, which is typically tightly regulated. Aberrant Hedgehog signaling is implicated in cancer. GeneCards: PTCH1
• SEMA4A (Semaphorin 4A): Involved in immune regulation and neurogenesis. In fibroblasts, it may modulate immune cell interactions or contribute to tissue repair processes.

Markers Enriched in Tumor Fibroblasts (Cancer-Associated Fibroblasts - CAFs)

The markers highly expressed in tumor fibroblasts are indicative of their activated state and their multifaceted roles in supporting tumor growth, invasion, and metastasis in the colon cancer microenvironment.

• FAP (Fibroblast Activation Protein): A canonical marker of CAFs in many cancers, including colon cancer. FAP is a serine protease expressed on the surface of activated fibroblasts. It plays a critical role in extracellular matrix (ECM) remodeling, promoting tumor invasion, angiogenesis, and immunosuppression. FAP+ CAFs contribute to desmoplasia, creating a stiff and dense ECM that facilitates tumor progression. GeneCards: FAP
• PDGFRB (Platelet-Derived Growth Factor Receptor Beta): A receptor tyrosine kinase that, upon ligand binding (e.g., PDGF-BB), promotes fibroblast proliferation, migration, and ECM production. PDGFRB signaling is crucial for CAF activation, angiogenesis, and tumor growth. GeneCards: PDGFRB
• CD276 (B7-H3): An immune checkpoint molecule belonging to the B7 family, expressed on various immune and tumor cells. In CAFs, CD276 acts as an immune suppressor, inhibiting T-cell activation and proliferation, thereby contributing to the "cold" or immunosuppressive TME in colon cancer. GeneCards: CD276
• ITGAV (Integrin Subunit Alpha V), ITGA5 (Integrin Subunit Alpha 5), ITGB5 (Integrin Subunit Beta 5), ITGA1 (Integrin Subunit Alpha 1): Integrins are cell surface receptors that mediate cell-ECM and cell-cell adhesion. High expression of these integrins in CAFs suggests their active involvement in interacting with the ECM, modulating matrix stiffness, cell migration, and signaling pathways crucial for tumor progression. They often heterodimerize (e.g., ITGAV with ITGB5, ITGA5 with ITGB1) to form functional receptors. GeneCards: ITGAV, GeneCards: ITGA5, GeneCards: ITGB5, GeneCards: ITGA1
• PLAUR (Plasminogen Activator, Urokinase Receptor): Also known as uPAR, it binds urokinase-type plasminogen activator (uPA), forming a complex involved in proteolysis of the ECM, cell migration, invasion, and angiogenesis. Elevated PLAUR in CAFs facilitates tumor metastasis. GeneCards: PLAUR
• NOTCH3 (Notch Receptor 3): Part of the Notch signaling pathway, which regulates cell fate decisions, proliferation, and differentiation. In CAFs, NOTCH3 signaling can promote CAF activation, angiogenesis, and maintain an immunosuppressive TME. GeneCards: NOTCH3
• EDNRA (Endothelin Receptor Type A): A G protein-coupled receptor for endothelin peptides. Activation of EDNRA in CAFs can promote proliferation, migration, and ECM production, contributing to tumor growth and fibrosis. GeneCards: EDNRA
• SEMA7A (Semaphorin 7A): A glycosylphosphatidylinositol-anchored semaphorin that can activate immune cells and fibroblasts. In CAFs, SEMA7A may modulate immune responses and promote pro-tumorigenic signaling.
• ANTXR1 (Anthrax Toxin Receptor 1): Also known as TEM8 (tumor endothelial marker 8), this protein is involved in angiogenesis and cell adhesion. Its expression in CAFs can contribute to tumor vascularization and interaction with the microenvironment.
• PMEPA1 (Prostate Transmembrane Protein, Androgen Induced 1): A transmembrane protein that regulates TGF-β signaling. Its upregulation in CAFs can enhance TGF-β responses, leading to increased ECM production and immunosuppression. GeneCards: PMEPA1
• F2R (F2R Coagulation Factor II Thrombin Receptor): Also known as PAR1, a thrombin receptor. Activation of PAR1 on CAFs can promote inflammatory responses, ECM remodeling, and tumor progression.
• ADAM19 (ADAM Metallopeptidase Domain 19): A member of the ADAM (A Disintegrin And Metalloprotease) family, involved in shedding of cell surface proteins and ECM remodeling. Its upregulation in CAFs can contribute to invasive phenotypes.

Clinical or Translational Implications

The distinct surfaceome profiles of normal versus tumor fibroblasts present significant opportunities for targeted therapies and biomarker development in colon cancer.

Therapeutic Targets

Markers highly expressed on tumor fibroblasts but minimally on adjacent normal fibroblasts are prime candidates for therapeutic intervention to reprogram or eliminate pro-tumorigenic CAFs without severely impacting normal tissue.

FAP (Fibroblast Activation Protein):

• Therapeutic Potential: FAP is one of the most promising targets for CAF-directed therapies. Its widespread expression on CAFs across many solid tumors, including colon cancer, and limited expression in most normal adult tissues make it an attractive target. Targeting FAP can reduce desmoplasia, enhance drug delivery, and potentially modulate immune suppression.
• Relevant Agents: FAP-targeting strategies are under active investigation, including FAP-specific antibodies (e.g., sibrotuzumab, although clinical trials showed limited efficacy, next-generation agents are being developed), FAP-activated prodrugs, FAP-specific CAR T-cells, and FAP-targeted radioligand therapies (e.g., FAP-2286). PubMed search for FAP targeted therapy cancer

PDGFRB (Platelet-Derived Growth Factor Receptor Beta):

• Therapeutic Potential: Inhibiting PDGFRB signaling can reduce CAF proliferation, migration, and ECM production, thereby sensitizing tumors to conventional therapies and impairing angiogenesis.
• Relevant Agents: Tyrosine kinase inhibitors (TKIs) targeting PDGFRB (e.g., imatinib, sunitinib, regorafenib) are approved for various cancers, and their potential in combination with other agents to target CAFs in colon cancer is being explored.

CD276 (B7-H3):

• Therapeutic Potential: As an immune checkpoint molecule, B7-H3 inhibition could reverse CAF-mediated immunosuppression, making the TME more conducive to anti-tumor immunity. It also has direct anti-tumor effects in some contexts.
• Relevant Agents: Monoclonal antibodies targeting B7-H3 (e.g., enoblituzumab, MGA271) are in clinical trials for various solid tumors.

Integrins (e.g., ITGAV, ITGA5, ITGB5):

• Therapeutic Potential: Integrins play crucial roles in CAF-ECM interactions, cell signaling, and tumor invasion. Blocking specific integrins on CAFs could inhibit their pro-tumorigenic functions.
• Relevant Agents: Integrin inhibitors (e.g., cilengitide, volociximab) have been developed and tested in clinical trials, primarily targeting tumor cells or endothelial cells, but their application to CAF-specific integrins is a growing area of interest.

PLAUR (uPAR):

• Therapeutic Potential: Inhibiting uPAR activity could reduce ECM degradation, cell migration, and angiogenesis, thus curbing tumor invasion and metastasis.
• Relevant Agents: uPAR antagonists and blocking antibodies are under investigation for their anti-cancer properties.

NOTCH3 (Notch Receptor 3):

• Therapeutic Potential: Targeting NOTCH3 signaling in CAFs could disrupt multiple pro-tumorigenic pathways, including angiogenesis and immune evasion.
• Relevant Agents: Gamma-secretase inhibitors (GSIs) are broad Notch pathway inhibitors, while more specific NOTCH3 antibodies or inhibitors are under development.

EDNRA (Endothelin Receptor Type A):

• Therapeutic Potential: Blocking EDNRA could reduce CAF-mediated fibrosis, proliferation, and potentially normalize tumor vasculature.
• Relevant Agents: EDNRA antagonists (e.g., atrasentan, zibotentan) have been evaluated in oncology settings for their anti-fibrotic and anti-proliferative effects.

Biomarkers and Experimental Validation

• Diagnostic/Prognostic Biomarkers: High expression of CAF-specific markers like FAP, PDGFRB, and CD276 in patient tumor biopsies (e.g., via immunohistochemistry) could serve as prognostic indicators for disease progression or recurrence in colon cancer.
• Predictive Biomarkers: The presence and abundance of these CAF markers might predict response to stromal-targeted therapies or immunotherapies.

Experimental Validation:

• In situ validation: Confirming protein expression of identified markers using immunohistochemistry (IHC) or immunofluorescence (IF) on colon cancer tissue arrays, correlating with clinical outcomes.
• Functional assays: Investigating the impact of modulating these markers in CAF cell lines (e.g., using CRISPR-Cas9, siRNA/shRNA) on proliferation, migration, invasion, and ECM remodeling.
• In vivo models: Testing the efficacy of targeted therapies against these markers in patient-derived xenograft (PDX) models or genetically engineered mouse models (GEMMs) of colon cancer.
• Single-cell spatial transcriptomics/proteomics: To validate co-localization of these markers with other cell types in the TME and their precise spatial relationships.

18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in CD4+ T cells isolated from 'Adj_normal' (adjacent normal) versus 'Tumor' tissues in the context of colon cancer. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual patient samples grouped by condition. The analysis specifically focused on surfaceome markers, identifying up to 40 markers per condition based on criteria including expression score, fold change, and percentage of expressing cells. This approach helps in understanding the phenotypic changes in CD4+ T cells within the tumor microenvironment (TME) and identifying potential diagnostic or therapeutic targets.

Visual Summary

The dot plot displays a clear distinction in the expression patterns of surface markers on CD4+ T cells between 'Adj_normal' and 'Tumor' samples.

• Adj_normal CD4+ T cells (left block): A distinct cluster of markers shows high expression and prevalence in CD4+ T cells from adjacent normal tissues. Key markers include IL7R, GPR183, CD48, KLRB1, MYADM, SLC2A3, PTGER4, GLIPR1, CD55, ATP1A1, ADGRE5, and TRAT1. These markers generally exhibit strong expression (dark red dots) and high fractions of expressing cells (large dots) across most 'Adj_normal' samples (SMC01-N to SMC10-N).
• Tumor CD4+ T cells (right block): Conversely, another set of markers is predominantly expressed in CD4+ T cells within tumor samples. These include CD74, TNFRSF4 (OX40), LY6E, TNFRSF18 (GITR), TIGIT, TNFRSF25, HLA-DPB1, and HLA-DPA1. These markers show robust expression and high prevalence in the 'Tumor' samples (SMC01-T to SMC25-T), while their expression is largely absent or very low in 'Adj_normal' samples.
• Sample-specific variability: While general patterns are clear, some inter-sample variability is observed. For instance, SMC04-T shows some expression of IL7R, GPR183, CD48, and KLRB1 which are characteristic of normal tissue, suggesting potential heterogeneity or admixture.
• Marker specificity: The two sets of markers are largely mutually exclusive between the 'Adj_normal' and 'Tumor' conditions, indicating significant phenotypic shifts in CD4+ T cells in the colon cancer TME.

Biological Interpretation

The differential expression of surface markers highlights distinct functional states of CD4+ T cells in the colon cancer tumor microenvironment compared to adjacent normal tissue.

Markers Elevated in Adj_normal CD4+ T cells:

Many of these markers are associated with quiescent, homeostatic, or early activation states of T cells in healthy tissue.

• IL7R (CD127): This receptor is crucial for T cell development, survival, and maintaining peripheral T cell homeostasis. Its high expression in normal tissue CD4+ T cells suggests a healthy, homeostatic T cell population, capable of survival and expansion upon antigen encounter. Signaling through IL7R is mediated by JAK-STAT pathways, essential for T cell proliferation and differentiation [PubMed Link: IL7R Signaling].
• GPR183 (EBI2): A G protein-coupled receptor involved in B cell migration within lymphoid organs, also expressed on certain T cell subsets. Its role in T cells is less defined but may relate to their localization or activation state in healthy tissue [GeneCards: GPR183].
• KLRB1 (CD161): Expressed on NK cells and subsets of T cells (including MAIT cells). It's associated with innate-like functions and often seen on T cells residing in mucosal tissues. Its presence in normal colon CD4+ T cells could indicate a resident memory or innate-like T cell population contributing to mucosal immunity [UniProt: KLRB1].
• PTGER4 (EP4): Prostaglandin E2 receptor 4, which mediates immunosuppressive effects of PGE2. While often associated with immune evasion in cancer, its expression in normal T cells might reflect a homeostatic regulatory role.

Markers Elevated in Tumor CD4+ T cells:

The markers upregulated in tumor-associated CD4+ T cells reflect an activated, often exhausted, or regulatory phenotype characteristic of the immune response within the TME.

• CD74, HLA-DPB1, HLA-DPA1 (MHC Class II components): While classically known for presenting antigens on antigen-presenting cells (APCs), the expression of MHC class II molecules (like HLA-DPA1 and HLA-DPB1) and the invariant chain CD74 on T cells can indicate specific activated states, such as T regulatory cells (Tregs) or T follicular helper (Tfh) cells, or T cells with antigen-presenting capabilities. This can be crucial for direct T cell-T cell interactions in the TME, influencing immune regulation [PubMed Link: MHC Class II on T cells].
• TNFRSF4 (OX40) and TNFRSF18 (GITR): These are co-stimulatory receptors belonging to the TNF receptor superfamily. When engaged by their ligands (OX40L and GITRL, respectively), they enhance T cell activation, proliferation, survival, and cytokine production, while also mitigating Treg-mediated suppression. Their upregulation suggests an active, yet potentially dysregulated, immune response in the TME [PubMed Link: OX40 Signaling, PubMed Link: GITR Signaling].
• TIGIT: T cell immunoreceptor with Ig and ITIM domains. TIGIT is an immune checkpoint receptor that, upon binding to its ligands (e.g., CD155, CD112), inhibits T cell activation and proliferation, leading to T cell exhaustion. Its high expression on tumor-infiltrating CD4+ T cells is a hallmark of an exhausted phenotype, characteristic of chronic antigen exposure in cancer [PubMed Link: TIGIT Immune Checkpoint].
• LY6E: Lymphocyte antigen 6 complex locus E. While its precise role in T cells within the TME is still being elucidated, LY6E has been linked to T cell activation and has been observed to be upregulated in various cancer contexts, potentially contributing to cancer progression or immune dysregulation [GeneCards: LY6E].

The overall picture suggests that CD4+ T cells in the colon tumor microenvironment are in a highly activated state, as indicated by co-stimulatory receptors (OX40, GITR), but simultaneously exhibit markers of exhaustion (TIGIT) and potentially altered antigen presentation capabilities (MHC class II). This delicate balance dictates the efficacy of the anti-tumor immune response.

Clinical or Translational Implications

The identified condition-specific surfaceome markers offer significant potential for clinical applications, particularly in colon cancer.

Diagnostic and Prognostic Biomarkers:

• TIGIT, OX40, GITR, HLA-DPA1/DPB1: The differential expression of these markers can serve as diagnostic indicators for distinguishing tumor-infiltrating CD4+ T cells from those in normal tissue. High expression of TIGIT on CD4+ T cells might correlate with advanced disease or poor prognosis due to T cell exhaustion, while OX40/GITR expression could indicate a more active immune response. These markers could be assessed via flow cytometry or immunohistochemistry in biopsy samples to characterize the immune landscape of colon tumors.

Therapeutic Targets and Agents:

The markers elevated in tumor CD4+ T cells represent promising targets for cancer immunotherapy.

• TIGIT: As an inhibitory immune checkpoint, TIGIT is a prime target for blockade therapy. Anti-TIGIT monoclonal antibodies are under clinical investigation to reinvigorate exhausted T cells and enhance anti-tumor immunity, often in combination with anti-PD-1/PD-L1 therapies.
• Therapeutic Agents: Tiragolumab, Vibostolimab [PubMed Search: TIGIT immunotherapy colon cancer].
• TNFRSF4 (OX40) and TNFRSF18 (GITR): As co-stimulatory receptors, agonists targeting OX40 and GITR aim to boost anti-tumor immune responses by enhancing T cell activation, proliferation, and effector functions.
• Therapeutic Agents: Several agonistic antibodies against OX40 (e.g., MEDI6469, MOXR0916) and GITR (e.g., TRX518, BMS-986126) are in clinical trials for various cancers, including solid tumors [PubMed Search: OX40 agonists cancer, PubMed Search: GITR agonists cancer].
• HLA-DPA1/DPB1/CD74: While not direct therapeutic targets in the same vein as checkpoint molecules, their expression on CD4+ T cells might identify subsets of T cells with unique regulatory or antigen-presenting functions within the TME. Understanding these subsets could lead to novel cell-based therapies or strategies to modulate their function.

Further research into the specific roles of these CD4+ T cell subsets in colon cancer progression and response to therapy is warranted. Validating these surface markers across larger patient cohorts and correlating them with clinical outcomes could facilitate the development of personalized immunotherapeutic strategies for colon cancer patients.

19. Differential Expression of Cell Cycle Pathway Genes in Colon Cancer Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression of a curated set of cell cycle pathway genes in Intestinal Epithelial cells, comparing "Tumor" samples to "Adj_normal" (adjacent normal) samples. The goal was to identify genes within this pathway that exhibit statistically significant differences in expression between these two conditions. The results are presented as box plots showing the "expressing cell fraction (sample)," which represents the proportion of cells within each patient sample that express the gene.

Visual Summary

The visualization displays 24 box plots, each representing a distinct cell cycle-related gene.

• For every gene presented, a highly statistically significant difference in expressing cell fraction is evident between the "Adj_normal" and "Tumor" conditions, as indicated by the p-values displayed above each plot (ranging from 8.98e-11 to 3.19e-06).
• A consistent and pronounced pattern is observed across all 24 genes: the median expressing cell fraction is markedly higher in the "Tumor" condition compared to the "Adj_normal" condition.
• The distributions of expressing cell fractions in tumor samples generally show higher medians and interquartile ranges, indicating a greater proportion of Intestinal Epithelial cells in tumor tissue are actively expressing these cell cycle genes. Conversely, adjacent normal samples exhibit lower and often tighter distributions of expressing cell fractions, reflecting lower transcriptional activity for these genes.

Biological Interpretation

The consistent and significant upregulation of these 24 cell cycle pathway genes in Intestinal Epithelial cells within the tumor microenvironment provides compelling evidence of highly active and dysregulated cell proliferation. This aligns with fundamental hallmarks of cancer, where uncontrolled cell division is a defining characteristic [1].

• Pervasive Activation of Proliferative Machinery: The observed increase in the "expressing cell fraction" for these genes in tumor cells suggests that a larger proportion of cells in the tumor are actively engaged in the cell cycle. This points to an overall acceleration of cell division processes, a critical driver of tumor growth in colon cancer, which is known to originate from Intestinal Epithelial cells.

Key Cell Cycle Regulators and Oncogenes

• Anaphase-Promoting Complex (APC/C) Components: Genes like ANAPC1, ANAPC10, ANAPC11, ANAPC13, CDC16, CDC26, CUL1, FZR1, and RBX1 are part of or regulate the APC/C, a crucial ubiquitin ligase that orchestrates progression through mitosis and entry into G1. Their elevated expression implies heightened mitotic activity and potentially altered APC/C regulation essential for sustained proliferation in tumor cells [2].
• Cyclins and CDK Activators: CCND1 (Cyclin D1) is a central regulator of the G1-S phase transition, and its overexpression is a well-documented oncogenic event promoting cell cycle progression [3]. CDC25B is a phosphatase that activates cyclin-dependent kinases (CDKs), further accelerating cell cycle progression.
• DNA Replication Initiation: ORC2 and ORC4, components of the Origin Recognition Complex, are vital for initiating DNA replication. Their increased expression suggests an enhanced capacity for DNA synthesis in tumor cells, supporting rapid division [4].
• Spindle Assembly Checkpoint (SAC) Proteins: MAD2L2 and MAD1L1 are key players in the SAC, which ensures accurate chromosome segregation during mitosis. While maintaining genomic stability, their overexpression can also indicate mitotic stress or adaptive mechanisms in highly proliferative, often aneuploid, cancer cells [5].
• Transcription Factors and Tumor Suppressors: MYC is a powerful proto-oncogene frequently amplified or overexpressed in cancers, driving cell growth and division [11]. E2F4 and TFDP2 belong to the E2F transcription factor family, which regulate genes essential for cell cycle progression. RB1 (Retinoblastoma 1) is a tumor suppressor whose function is often lost in cancer, leading to uncontrolled proliferation and E2F-driven gene expression. The co-occurrence of RB1 upregulation with E2F activators may reflect complex feedback loops or compensatory mechanisms in tumor cells [6, 7].
• Chromatin Remodeling and Cohesin: HDAC2, a histone deacetylase, modifies chromatin structure and is implicated in cell cycle control and cancer progression. STAG2, a component of the cohesin complex, is critical for proper chromosome segregation, and its dysregulation can contribute to genomic instability.
• 14-3-3 Proteins: YWHAG and YWHAQ are members of the 14-3-3 protein family, involved in regulating diverse cellular processes including cell cycle, apoptosis, and signal transduction. Their overexpression can promote cell survival and proliferation in cancer [8].
• Relevance to Colon Cancer Context: The findings are highly relevant given that the Resolved tumor-origin cell type is Intestinal Epithelial cell, which is the cell of origin for colon cancer. The presence of Aneuploid cells (22.4% of total cells) within the dataset further supports the notion of aberrant cell division and genomic instability, which are direct consequences of the observed widespread dysregulation in these cell cycle pathways.

Clinical or Translational Implications

• Biomarkers for Colon Cancer: The significantly elevated expressing cell fraction of these cell cycle genes in Intestinal Epithelial cells from colon tumor samples positions them as potential biomarkers for early detection, prognosis, or monitoring treatment response in colon cancer. Established oncogenes like CCND1 and MYC further reinforce this potential.
• Therapeutic Targeting: Many of the upregulated genes are critical components of cell cycle control pathways that are actively pursued as therapeutic targets in oncology. For example:
• Inhibitors targeting cyclin-dependent kinases (e.g., CDK4/6 inhibitors for pathways influenced by CCND1) are clinically approved therapies in other cancers [9].
• Modulators of the APC/C complex are under investigation as potential anticancer agents [10].
• HDAC inhibitors, like those targeting HDAC2, are a class of anticancer drugs currently in clinical use [12].

The consistent reliance of tumor Intestinal Epithelial cells on these highly active cell cycle pathways suggests they may be particularly susceptible to therapeutic interventions that inhibit these processes, offering avenues for targeted drug development or repurposing.

• Understanding Disease Mechanisms: This analysis provides crucial insights into the fundamental proliferative mechanisms driving colon cancer in its cell of origin. Further investigation into the upstream signaling events that lead to the upregulation of these genes could uncover novel vulnerabilities and combination therapeutic strategies.

References

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. PubMed Search: "Hallmarks of cancer" review
2. Peters, J. M. (2006). The anaphase promoting complex/cyclosome: a machine that ubiquitinates and destroys. Current Opinion in Cell Biology, 18(6), 661-673. GeneCards: ANAPC1
3. Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011). Cyclin D1 regulation of cell cycle progression and cancer. Cell Cycle, 10(20), 3456-3467. GeneCards: CCND1
4. Blow, J. J., & Dutta, A. (2005). Preventing re-replication of chromosomal DNA. Nature Reviews Molecular Cell Biology, 6(6), 476-486. GeneCards: ORC2
5. Foley, E. A., & Pines, J. (2015). How to make a spindle: coordinating the anaphase-promoting complex/cyclosome with spindle assembly. Current Opinion in Cell Biology, 34, 1-10. GeneCards: MAD2L2
6. Kent, L. N., & Leone, G. (2019). The broken cycle: E2F in cancer. Nature Reviews Cancer, 19(6), 324-338. GeneCards: E2F4
7. Morris, E. J., & Gualberto, A. (2017). The Retinoblastoma tumor suppressor: a master regulator of cell cycle, differentiation and oncogenesis. Seminars in Cancer Biology, 45, 1-13. GeneCards: RB1
8. Yang, X., Cao, L., Chen, G., Zhang, X., Li, X., Wu, X., & Liu, F. (2020). The 14-3-3 protein family and cancer. Journal of Experimental & Clinical Cancer Research, 39(1), 84. GeneCards: YWHAG
9. O'Leary, B., Finn, R. S., & Turner, N. C. (2016). Targeting the cell cycle in breast cancer: a review of CDK4/6 inhibitors. ESMO Open, 1(1), e000032. PubMed Search: "CDK4/6 inhibitors" cancer
10. Lu, Y., & Liang, W. (2018). Targeting anaphase-promoting complex/cyclosome (APC/C) for cancer therapy. Current Drug Targets, 19(13), 1500-1507. PubMed Search: "APC/C inhibitors" cancer therapy
11. Dang, C. V., Resar, G. S., & Emison, E. (1999). Function of the c-Myc oncogene. Oncogene, 18(38), 6296-6302. GeneCards: MYC
12. Xu, L., & Zhang, W. (2018). Histone deacetylase inhibitors: Molecular mechanisms and clinical implications. Acta Pharmacologica Sinica, 39(5), 711-717. PubMed Search: "HDAC inhibitors" cancer

20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results, specifically Gene Set Analysis (GSA), for Intestinal Epithelial cells. The GSA was performed by comparing up-regulated differentially expressed genes (DEGs) in Intestinal Epithelial cells under three different conditions: 'Adj_normal' vs. others, 'Diploid' vs. others, and 'Tumor' vs. others. This approach identifies biological pathways and processes characteristic of each specific cellular state within the colon tissue, providing insights into normal physiological functions, homeostatic mechanisms, and tumor-associated dysregulations.

Visual Summary

The visualizations consist of three bar plots, each displaying the top enriched GO terms (pathways) based on up-regulated DEGs in Intestinal Epithelial cells for the specified comparison. The bars represent the statistical significance of enrichment, indicated by -log(p-val) and -log(q-val). Higher values denote stronger enrichment and greater statistical confidence.

• Adj_normal_vs_others: This plot shows numerous enriched metabolic pathways in adjacent normal intestinal epithelial cells. The most highly significant terms include 'Fatty acid degradation', 'Valine, leucine and isoleucine degradation', 'Non-alcoholic fatty liver disease', 'Mineral absorption', and various other metabolic processes. The -log(p-val) extends up to approximately 2.0, and -log(q-val) up to 1.5.
• Diploid_vs_others: This plot presents a more focused set of enriched terms in diploid intestinal epithelial cells, with significantly higher -log(p-val) and -log(q-val) values compared to the 'Adj_normal' comparison. Top terms are 'Ribosome', 'Coronavirus disease', 'Toll-like receptor signaling pathway', 'Viral protein interaction with cytokine and cytokine receptor', and 'NF-kappa B signaling pathway'. The -log(p-val) reaches over 40, and -log(q-val) over 35.
• Tumor_vs_others: This plot displays a broad and extensive list of enriched pathways in tumor-associated intestinal epithelial cells, indicating profound cellular reprogramming. The most significantly enriched terms, with -log(p-val) extending beyond 25 and -log(q-val) beyond 15, include 'Protein processing in endoplasmic reticulum', 'Amyotrophic lateral sclerosis', 'Spliceosome', 'RNA transport', 'Salmonella infection', 'Huntington disease', 'Ribosome', 'Pathways of neurodegeneration', 'Cell cycle', 'Ubiquitin mediated proteolysis', 'Autophagy', 'mTOR signaling pathway', 'p53 signaling pathway', and directly relevant pathways like 'Colorectal cancer'. A notable feature is the high number of infection-related pathways and those associated with neurodegenerative diseases, reflecting general cellular stress and dysregulation.

Biological Interpretation

Intestinal Epithelial Cells in Adjacent Normal Colon Tissue (Adj_normal_vs_others)

The enrichment of metabolic pathways like 'Fatty acid degradation', 'Valine, leucine and isoleucine degradation', 'Butanoate metabolism', and 'PPAR signaling pathway' suggests that adjacent normal intestinal epithelial cells are actively engaged in diverse metabolic activities. 'Mineral absorption' highlights a core physiological function of the intestinal epithelium. These findings reflect the normal metabolic homeostasis and absorptive roles expected for healthy intestinal cells. The term 'Non-alcoholic fatty liver disease' appearing here may indicate a general metabolic shift or stress response pathway, not necessarily liver-specific pathology, but rather metabolic alterations that can occur in various tissues.

Diploid Intestinal Epithelial Cells (Diploid_vs_others)

The highly significant enrichment of 'Ribosome' indicates active protein synthesis, which is fundamental for cell growth, maintenance, and functional activity. The prominent enrichment of 'Toll-like receptor signaling pathway', 'Viral protein interaction with cytokine and cytokine receptor', 'NF-kappa B signaling pathway', 'Chemokine signaling pathway', and specific infectious diseases like 'Coronavirus disease' and 'Human cytomegalovirus infection' points towards a robust immune surveillance and antiviral response capacity in diploid intestinal epithelial cells. This suggests that these cells, likely representing healthy or less transformed states, are actively involved in detecting and responding to pathogens and maintaining immune integrity within the gut lumen [PubMed search: Toll-like receptor intestinal immunity]. 'mRNA surveillance pathway' further supports cellular quality control mechanisms.

Tumor-Associated Intestinal Epithelial Cells (Tumor_vs_others)

The GSA results for tumor-associated intestinal epithelial cells reveal extensive cellular reprogramming characteristic of malignancy:

• Protein Synthesis and Processing Dysregulation: Pathways such as 'Protein processing in endoplasmic reticulum', 'Spliceosome', 'RNA transport', 'Ribosome', 'RNA degradation', and 'Proteasome' are highly enriched. This signifies a profound alteration in gene expression, protein synthesis, folding, and degradation machinery, essential for the rapid proliferation and survival of cancer cells. Increased ER stress is a common feature in fast-growing tumors [PubMed search: ER stress cancer].
• Cell Cycle and Growth Control: The enrichment of 'Cell cycle', 'Cellular senescence', 'mTOR signaling pathway', 'p53 signaling pathway', and 'FoxO signaling pathway' directly points to dysregulated cell proliferation, altered growth factor signaling, and evasion of normal cell cycle checkpoints and senescence, which are hallmarks of cancer [GeneCards: TP53; GeneCards: MTOR].
• Metabolic Reprogramming and Stress Response: 'Oxidative phosphorylation' suggests altered energy metabolism, a known feature in many cancers (Warburg effect and mitochondrial reprogramming) [PubMed search: cancer metabolic reprogramming]. Pathways related to 'Autophagy', 'Ubiquitin mediated proteolysis', and general neurodegenerative disease terms (e.g., 'Amyotrophic lateral sclerosis', 'Huntington disease', 'Parkinson disease') often reflect shared cellular stress responses, protein misfolding, and degradation mechanisms that are dysregulated in cancer to promote survival or maintain cellular homeostasis under oncogenic stress.
• Inflammation and Infection-Related Pathways: The frequent appearance of pathways linked to bacterial (e.g., 'Salmonella infection', 'Shigellosis', 'Pathogenic Escherichia coli infection') and viral infections (e.g., 'Human T-cell leukemia virus 1 infection', 'Human papillomavirus infection', 'Epstein-Barr virus infection', 'Coronavirus disease', 'Hepatitis B', 'Viral carcinogenesis') is striking. This could indicate a chronically inflamed tumor microenvironment, altered gut microbiome, or the activation of general immune and stress responses that can be co-opted by tumor cells. Chronic inflammation is a significant risk factor for colorectal cancer [PubMed search: inflammation colon cancer].
• Cell Adhesion and Junctions: The enrichment of 'Tight junction' and 'Adherens junction' pathways suggests alterations in cell-cell adhesion, which is crucial for epithelial integrity and is frequently compromised during tumor invasion and metastasis [PubMed search: cell adhesion cancer metastasis].
• Direct Cancer Pathways: The direct enrichment of 'Colorectal cancer' pathway, along with other specific cancer pathways (e.g., 'Chronic myeloid leukemia', 'Pancreatic cancer', 'Renal cell carcinoma', 'Small cell lung cancer', 'Prostate cancer'), further validates the presence of cancer-specific transcriptional programs within these cells, highlighting common oncogenic mechanisms shared across various tumor types.

Clinical or Translational Implications

The GSA results for tumor-associated Intestinal Epithelial cells provide a rich source of potential clinical and translational insights for colon cancer:

• Biomarker Discovery: The highly dysregulated pathways, such as those involved in protein processing (e.g., ER stress markers), cell cycle control (e.g., cyclins, CDKs), and specific signaling cascades (mTOR, p53), represent potential diagnostic or prognostic biomarkers.
• Therapeutic Targets: Pathways like mTOR signaling and oxidative phosphorylation are already targets for existing or experimental cancer therapies. The broad dysregulation of protein synthesis, folding, and degradation machinery suggests that targeting components of the proteasome or ER stress response could be effective therapeutic strategies for colon cancer [PubMed search: proteasome inhibitors cancer].
• Immuno-oncology Implications: The strong enrichment of infection and immune-related pathways in tumor cells highlights the complex interplay between the tumor and its microenvironment, including microbial factors and immune responses. This could inform strategies for immunotherapy or interventions targeting the gut microbiome in colon cancer [PubMed search: gut microbiome cancer immunotherapy].
• Disease Mechanism Understanding: The involvement of neurodegenerative-like pathways suggests common cellular stress responses that could be therapeutically exploited, even if the primary pathology is different. The altered cell-cell adhesion pathways ('Tight junction', 'Adherens junction') may offer targets to impede tumor invasion and metastasis.

21. Gene Set Enrichment Analysis (GSEA) Across Cell Types and Conditions in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results for various cell types identified in colon tissue, comparing gene expression patterns in different conditions. The plot_gsea_go tool was utilized to visualize enrichment scores for 120 selected pathways. Each data point in the plot represents the enrichment of a specific gene set (pathway) within a particular cell type and condition, relative to all other cells and conditions in the dataset (indicated by "vs_others"). The analysis focuses on distinguishing unique functional signatures of cell populations in Tumor tissue versus Adj_normal tissue. The RdBu_r colormap is used, where red indicates positive enrichment (upregulation of genes in the pathway) and blue indicates negative enrichment (downregulation). The size of the dot reflects the statistical significance (-log(P-value)).

Visual Summary

The dot plot visualizes GSEA results across 10 cell types, each analyzed in Adj_normal vs_others and Tumor vs_others conditions. Additionally, Intestinal Epithelial cell is further stratified by ploidy status (Diploid vs_others, Aneuploid vs_others).

Key visual patterns include:

• Differential Enrichment by Condition: There is a clear shift in pathway enrichment patterns when comparing Adj_normal vs_others and Tumor vs_others for most cell types. Pathways typically associated with cancer (e.g., Wnt signaling, Colorectal cancer, MAPK signaling, Glycolysis / Gluconeogenesis) show strong positive enrichment (large red dots) in Tumor vs_others columns, particularly in Intestinal Epithelial cell, Fibroblast, and Macrophage. Conversely, these pathways often show negative enrichment (blue dots) or no significant enrichment in Adj_normal vs_others columns.
• Cell Type Specificity: While some pathways are broadly enriched across multiple cell types in the tumor microenvironment (e.g., Wnt, MAPK, TNF signaling), others show more cell-type-specific patterns. For instance, "T cell receptor signaling pathway" is primarily enriched in T cells, and "B cell receptor signaling pathway" in B cells.
• Intestinal Epithelial Cell as Tumor Origin: The Intestinal Epithelial cell: Tumor vs_others and Intestinal Epithelial cell: Aneuploid vs_others columns display the most pronounced and widespread positive enrichment for cancer-related pathways, consistent with this cell type being the resolved tumor-origin cell.
• Significance: The size of the dots, representing the -log(P-value), indicates a high level of statistical significance for many of the observed enrichments, especially for pathways critical to tumor biology.

Biological Interpretation

The GSEA results provide strong biological insights into the functional state of different cell types within the colon cancer microenvironment.

1. Tumor-Origin Intestinal Epithelial Cells (IECs) Exhibit Hallmark Cancer Pathways:

• Intestinal Epithelial cell: Tumor vs_others shows highly significant positive enrichment for established cancer pathways such as "Colorectal cancer," "Wnt signaling pathway," "ErbB signaling pathway," and "MAPK signaling pathway". These pathways are crucial for cell proliferation, survival, and differentiation, and their aberrant activation is a hallmark of colorectal carcinogenesis PubMed search: Wnt signaling colorectal cancer.
• Metabolic reprogramming, indicated by positive enrichment of "Glycolysis / Gluconeogenesis," "Citrate cycle (TCA cancer)," "Fatty acid elongation," and "Pentose phosphate pathway," is also a prominent feature of tumor IECs, reflecting the Warburg effect and altered biosynthesis needed for rapid cell growth PubMed search: cancer metabolism glycolysis.
• The similarity in pathway enrichment between Intestinal Epithelial cell: Tumor vs_others and Intestinal Epithelial cell: Aneuploid vs_others further supports the cancerous nature of these cells, as aneuploidy is a common characteristic of tumor cells.

2. Activated Stromal Compartment Supporting Tumor Growth:

• Fibroblast: Tumor vs_others and Endothelial cell: Tumor vs_others exhibit strong positive enrichment for "Focal adhesion," "Cell adhesion molecules," and "Fluid shear stress and atherosclerosis." These pathways highlight active extracellular matrix (ECM) remodeling, angiogenesis, and mechanotransduction processes, characteristic of cancer-associated fibroblasts (CAFs) and tumor-associated endothelial cells. CAFs play a critical role in promoting tumor progression, invasion, and metastasis by modifying the tumor microenvironment GeneCards: ECM remodeling cancer.
• These stromal cells also show enrichment for "Wnt signaling pathway," "MAPK signaling pathway," and "TNF signaling pathway," suggesting that broader inflammatory and developmental signals contribute to the activation and pro-tumorigenic functions of the tumor stroma.

3. Dysregulated Immune Cell Responses in the Tumor Microenvironment:

• Macrophage: Tumor vs_others shows positive enrichment for "TNF signaling pathway," "Phagosome," and "Glycolysis / Gluconeogenesis." This profile suggests an activation state that may be skewed towards a tumor-associated macrophage (TAM) phenotype, which often promotes immune suppression, angiogenesis, and tumor growth PubMed search: tumor associated macrophages colon cancer.
• T cell CD4+: Tumor vs_others and T cell CD8+: Tumor vs_others both show enrichment for "T cell receptor signaling pathway," "TNF signaling pathway," "MAPK signaling pathway," and "Apoptosis." While TCR signaling indicates active T cells, the enrichment of "Apoptosis" could suggest T cell exhaustion or programmed cell death within the harsh tumor microenvironment, contributing to immune evasion. The Th17 cell differentiation enrichment in CD4+ T cells suggests a complex immune response, as Th17 cells can have both anti-tumor and pro-tumor roles depending on the context.
• Plasma cell: Tumor vs_others and B cell: Tumor vs_others also show activation of "Wnt signaling pathway," "TNF signaling pathway," and "MAPK signaling pathway," suggesting their involvement in the broader inflammatory and signaling landscape of the tumor. Plasma cells show specific enrichment for "Intestinal immune network for IgA production" and pathways related to protein synthesis and export, consistent with their antibody-producing function.

Clinical or Translational Implications

The comprehensive GSEA results point to several potential clinical and translational avenues for colon cancer:

• Therapeutic Targets: The widespread and significant enrichment of Wnt, MAPK, and TNF signaling pathways across multiple tumor-associated cell types suggests that targeting these pathways could be a highly effective therapeutic strategy. Inhibitors of these pathways are already being investigated or are in clinical use for various cancers PubMed search: Wnt MAPK TNF inhibitors cancer.
• Metabolic Vulnerabilities: The metabolic reprogramming observed in tumor IECs and macrophages (e.g., enhanced glycolysis) highlights potential vulnerabilities for therapeutic intervention. Targeting tumor-specific metabolic pathways could selectively inhibit cancer cell growth and survival.
• Stromal-Targeted Therapies: The active ECM remodeling and angiogenesis signatures in fibroblasts and endothelial cells emphasize the importance of the tumor stroma. Therapies aimed at normalizing the tumor microenvironment, such as anti-angiogenic drugs or agents that modulate CAF activity, could hinder tumor progression and improve drug delivery.
• Immunotherapy Strategies: The identified dysregulation in immune cell pathways, including signs of T cell exhaustion (Apoptosis enrichment), suggests opportunities for immunotherapy. Combinatorial approaches that restore T cell function or modulate TAM phenotypes could enhance anti-tumor immunity.
• Biomarker Discovery: The specific pathway enrichments distinguishing tumor cells and their microenvironment from normal tissue could serve as valuable biomarkers for early detection, prognosis, or monitoring treatment response. For example, gene signatures derived from the enriched Wnt or MAPK pathways in tumor epithelial cells could be investigated as predictive markers.

22. Discussion

This comprehensive single-cell analysis provides a high-resolution view of the intricate cellular and molecular landscape of colon cancer. A central finding is the robust identification of the malignant Intestinal Epithelial cell population, characterized by significant aneuploidy and a profound upregulation of cell cycle genes, reflecting uncontrolled proliferation. This malignant epithelial compartment actively engages with its microenvironment, exhibiting marked shifts in cell-cell interaction patterns and surface marker expression compared to adjacent normal tissue.

The tumor microenvironment (TME) is profoundly remodeled. We observed a significant increase in immunosuppressive T regulatory (Treg) cells, alongside a decrease in CD8 Memory T cells, creating an immune-suppressive milieu. The macrophage compartment is expanded and highly dynamic, with a significant increase in M1, M2B, M2C, and M2D subsets in tumors, suggesting both inflammatory and pro-tumorigenic roles. Fibroblasts also undergo extensive activation, transitioning into cancer-associated fibroblasts (CAFs) marked by specific surface proteins (e.g., FAP), contributing to extracellular matrix remodeling and immune suppression.

Key oncogenic pathways are aberrantly activated. Epidermal Growth Factor Receptor (EGFR) amplification and activation, widespread TGF-beta signaling, and enhanced Wnt and MAPK signaling pathways are prominent across various tumor-associated cell types, driving proliferation, survival, and immune modulation. Cell-cell interaction analyses further delineate crucial communication axes, such as the SPP1-integrin interactions, CEACAM5 homotypic adhesion, and the CXCL12-CXCR4 axis, which collectively promote tumor growth, invasion, and angiogenesis. Notably, the immune checkpoint landscape is activated, with strong PD-1/PD-L1 interactions and TIGIT upregulation on T cells, underscoring active immune evasion mechanisms. These findings align with known hallmarks of colon cancer and provide a granular understanding of the cellular crosstalk that sustains malignancy, opening new avenues for targeted therapeutic strategies.

Hypotheses:

1. The observed genomic instability (aneuploidy) in Intestinal Epithelial cells drives their hyper-proliferative state and influences their altered cell-cell interaction patterns within the tumor microenvironment.
2. The increased proportion of Tregs and the expression of immune checkpoints like TIGIT on CD4+ T cells in the tumor microenvironment directly contribute to the suppression of anti-tumor immunity and predict a diminished response to standard therapies.
3. Cancer-Associated Fibroblasts (CAFs), identified by markers like FAP and PDGFRB, promote tumor progression and metastasis through extensive extracellular matrix remodeling and secretion of pro-tumorigenic factors such as CXCL12, fostering an immunosuppressive and angiogenic microenvironment.
4. Targeting key upregulated surface proteins (e.g., CEACAM5, EPCAM, SLC1A5) on tumor Intestinal Epithelial cells, or modulating specific cell-cell interaction pathways (e.g., SPP1-integrin, CXCL12-CXCR4) within the tumor microenvironment, will effectively inhibit tumor growth and metastasis in colon cancer.
5. The diverse macrophage polarization states (M1, M2B, M2C, M2D) in the tumor reflect distinct functional contributions to tumor progression and immune modulation, which can be therapeutically reprogrammed by targeting specific surface markers like CSF1R or TREM2.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): Frequent amplification and activation of EGFR in tumor Intestinal Epithelial cells drives cell proliferation, survival, and metastasis, making it a critical oncogenic driver in colon cancer. Evidence: CNV analysis identified frequent *EGFR* locus amplification (7p14.1:7q11.23) in 58% of tumor samples. CCI analysis highlighted elevated AREG-EGFR and HBEGF-EGFR interactions predominantly in aneuploid Intestinal Epithelial cells and fibroblasts within tumors. GSEA also showed enrichment for the ErbB signaling pathway in tumor IECs. Validation: Targeted sequencing or FISH for *EGFR* amplification, and immunohistochemistry for EGFR protein expression in tumor biopsies. In vitro studies with EGFR inhibitors on patient-derived tumor organoids. Clinical trials using anti-EGFR monoclonal antibodies (e.g., Cetuximab, Panitumumab) in RAS wild-type colorectal cancer.
2. CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 5): CEACAM5 is highly overexpressed on malignant intestinal epithelial cells and plays a role in cell adhesion, proliferation, survival, and metastasis, representing a well-established tumor-specific target. Evidence: Surfaceome marker analysis showed strong upregulation of CEACAM5 in tumor Intestinal Epithelial cells (large, dark red dots). CCI analysis identified prominent homotypic CEACAM5-CEACAM5 interactions among aneuploid Intestinal Epithelial cells, suggesting altered cell adhesion and potential cancer-specific signaling. Validation: Immunohistochemistry on tumor sections to confirm CEACAM5 protein expression and localization. Flow cytometry on dissociated tumor cells. Testing CEACAM5-targeted antibody-drug conjugates (ADCs) in patient-derived xenograft models of colon cancer.
3. FAP (Fibroblast Activation Protein): FAP is a canonical marker of activated Cancer-Associated Fibroblasts (CAFs), extensively involved in extracellular matrix remodeling, promoting tumor invasion, angiogenesis, and immunosuppression within the tumor microenvironment. Evidence: Surfaceome marker analysis demonstrated robust expression of FAP specifically in fibroblasts from tumor samples, with minimal to no expression in adjacent normal fibroblasts. Validation: Immunohistochemistry on colon cancer patient biopsies to quantify FAP+ CAF infiltration and correlate with clinical outcomes. In vitro functional assays to assess the impact of FAP inhibition on CAF-mediated matrix remodeling and pro-tumorigenic factor secretion. Efficacy studies with FAP-targeted therapies (e.g., radioligand therapies, ADCs) in preclinical colon cancer models.
4. PD-1/PD-L1 Axis (CD274/PDCD1): The robust activation of the PD-1/PD-L1 axis within the tumor microenvironment creates an immunosuppressive milieu, allowing tumor cells to evade anti-tumor T cell immunity. Evidence: CCI analysis (focused on immune checkpoint genes) revealed highly significant and strong CD274_PDCD1 -- Mac | T CD8+ interactions across numerous tumor samples. PD-L1 (CD274) expression was also noted on endothelial cells and aneuploid intestinal epithelial cells interacting with PD-1 (PDCD1) on T cells. Validation: Immunohistochemistry or multiplex immunofluorescence to assess PD-L1 expression on tumor cells, macrophages, and other TME components, and PD-1 expression on T cells. Correlation of expression patterns with patient response to immune checkpoint inhibitors (e.g., Pembrolizumab, Nivolumab) in clinical trials for colon cancer.
5. TIGIT (T cell immunoreceptor with Ig and ITIM domains): TIGIT is an inhibitory immune checkpoint receptor highly expressed on tumor-infiltrating CD4+ T cells, contributing to T cell exhaustion and dampened anti-tumor immune responses in the colon cancer microenvironment. Evidence: Surfaceome marker analysis showed robust and specific upregulation of TIGIT in CD4+ T cells isolated from tumor samples compared to those from adjacent normal tissue. Validation: Flow cytometry or mass cytometry to quantify TIGIT expression on CD4+ and CD8+ T cells in patient biopsies. In vitro functional assays demonstrating TIGIT blockade-mediated T cell reinvigoration. Clinical trials with anti-TIGIT antibodies (e.g., Tiragolumab) for colon cancer, often in combination with anti-PD-1/PD-L1 therapies.
6. CSF1R (Colony Stimulating Factor 1 Receptor): CSF1R signaling is crucial for the recruitment, survival, and differentiation of macrophages, including pro-tumorigenic tumor-associated macrophages (TAMs). Targeting CSF1R can deplete or reprogram TAMs, thereby reducing tumor growth and metastasis. Evidence: Surfaceome marker analysis identified CSF1R expression on macrophages. Additionally, the analysis indicated a significant increase in M1, M2B, M2C, and M2D macrophage subsets in tumor tissue, implying an expanded TAM population reliant on CSF1R signaling. Validation: Immunohistochemistry and flow cytometry to monitor TAM density and phenotype changes in tumor tissue following CSF1R inhibitor treatment in preclinical models or clinical trials. Correlation of TAM modulation with immune cell infiltration and tumor regression.
7. TGF-beta Signaling Pathway: Widespread activation of TGF-beta signaling in the colon cancer microenvironment orchestrates multiple pro-tumorigenic processes, including immune suppression, epithelial-mesenchymal transition (EMT), angiogenesis, and extensive stromal remodeling. Evidence: CCI analysis, particularly focusing on immune checkpoint and cell cycle genes, showed robust and multiple TGFB1/3-TGFbeta_receptor interactions involving aneuploid Intestinal Epithelial cells, fibroblasts, macrophages, endothelial cells, and T cells, which are highly active in tumor samples. GSEA results indicate enrichment for pathways related to EMT and cell adhesion, consistent with TGF-beta's role. Validation: Assessment of TGF-beta pathway activity (e.g., phosphorylated SMAD2/3) in tumor biopsies by immunohistochemistry. In vitro and in vivo studies to evaluate the impact of TGF-beta inhibition (e.g., using specific receptor antagonists or neutralizing antibodies) on tumor cell growth, metastasis, immune cell function, and TME composition in colon cancer models.
8. Cell Cycle Regulators (e.g., Cyclin D1/CDK4/6 axis): The widespread and highly significant upregulation of numerous cell cycle pathway genes in tumor Intestinal Epithelial cells drives uncontrolled proliferation, a fundamental hallmark of colon cancer. Evidence: Box plots demonstrated a statistically significant and marked increase in the 'expressing cell fraction' for 24 cell cycle-related genes, including *CCND1* (Cyclin D1), *MYC*, and various Anaphase-Promoting Complex (APC/C) components, specifically in Intestinal Epithelial cells from tumor samples. GSA confirmed strong enrichment for the 'Cell cycle' pathway in tumor IECs. Validation: Assessment of tumor cell proliferation (e.g., Ki67 expression) following treatment with cell cycle inhibitors (e.g., CDK4/6 inhibitors) in patient-derived organoids or xenograft models of colon cancer. Clinical trials exploring cell cycle-targeted therapies in colon cancer patients, particularly those with high expression of specific cell cycle drivers.

Follow-up validation ideas:

1. Spatial Transcriptomics/Proteomics: Use spatial transcriptomics or multiplex immunofluorescence to validate the co-localization of specific cell types (e.g., aneuploid Intestinal Epithelial cells, CAFs, TAMs, Tregs) and the identified cell-cell interaction pairs (e.g., PD-1/PD-L1, SPP1-integrin) within patient tumor sections, assessing their spatial proximity and correlation with clinical outcomes.
2. Flow Cytometry/Mass Cytometry (CyTOF): Quantify the proportions and phenotypic markers (e.g., TIGIT, OX40, GITR on T cells; FAP, PDGFRB on fibroblasts; CSF1R, GPNMB, TREM2 on macrophages) of immune and stromal cell subsets in larger cohorts of fresh colon cancer patient samples, correlating these with disease stage, prognosis, and response to neoadjuvant therapies.
3. Functional In Vitro/Ex Vivo Assays: Perform functional assays using patient-derived organoids (PDOs) or primary cell co-cultures (e.g., tumor epithelial cells with CAFs, TAMs, or T cells) to test the impact of inhibiting key signaling pathways (e.g., EGFR, TGF-beta, Wnt, MAPK) or blocking specific cell-cell interactions on tumor cell proliferation, invasion, and immune cell function. This could involve using specific small molecule inhibitors or neutralizing antibodies.
4. CRISPR-Cas9 or siRNA Perturbation Assays: Genetically perturb (knockout/knockdown) genes encoding critical surface markers (e.g., CEACAM5, SLC1A5, FAP) or receptor components (e.g., EGFR, CXCR4, TREM2) in colon cancer cell lines or PDOs, then assess the impact on proliferation, migration, metabolism, and immune evasion in co-culture models.
5. Patient-Derived Xenograft (PDX) or Genetically Engineered Mouse Models (GEMMs): Test the efficacy of novel therapeutic agents targeting identified pathways or surface markers (e.g., anti-CEACAM5 ADCs, FAP inhibitors, anti-TIGIT antibodies, CSF1R inhibitors, TGF-beta antagonists) in preclinical in vivo models of colon cancer, evaluating tumor growth, metastasis, and changes in the tumor immune microenvironment.
6. CNV-FISH Validation: Validate the recurrent chromosomal amplifications (e.g., EGFR, Chromosome 20q) and deletions (e.g., Chromosome 18) identified in Intestinal Epithelial cells using Fluorescent In Situ Hybridization (FISH) on tumor tissue sections, to confirm these genomic alterations at the single-cell level and correlate with tumor grade or clinical outcomes.

Limitations:

This report relies on single-cell RNA sequencing data, which provides transcriptional insights but does not directly capture protein levels or post-translational modifications. Inferences about cell identity, ploidy, and cell-cell interactions are based on computational predictions and published knowledge, requiring further experimental validation. The data is cross-sectional, limiting conclusions about causality or temporal disease progression. Inter-sample and intra-tumor heterogeneity observed underscore that findings may not apply universally to all colon cancer patients. The specific stage or molecular subtype of colon cancer is not fully resolved, impacting the generalizability of some findings.

23. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns. save
2. Show major cell type scores on UMAP and save the result. save
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values. save
4. Select Intestinal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results. save
5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns. save
6. Show and save a population bar plot of minor cell types. save
7. Show and save a population bar plot of T cell subsets. save
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels. save
9. Show and save a population bar plot of macrophage subsets. save
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels. save
11. Select Intestinal Epithelial cells, show their ploidy populations as a bar plot, and save the result. save
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cells, Fibroblast cells, Macrophage cells, T cells, and other relevant cell types. Select at most 80 cell-cell interactions per group. save
13. Find cell-cell interactions involving Intestinal Epithelial cells, T cells, B cells, Macrophage cells, Fibroblast cells, and Endothelial cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents. save
14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Intestinal Epithelial cells, T cells, B cells, Macrophage cells, Fibroblast cells, and Endothelial cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents. save
15. Show marker expressions for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence. save
16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information. save
17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information. save
18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information. save
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3. save
20. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot. save
21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None. save